1
|
Fages V, Bourre F, Larrue R, Wenzel A, Gibier JB, Bonte F, Dhaenens CM, Kidd K, Kmoch S, Bleyer A, Glowacki F, Grunewald O. Description of a New Simple and Cost-Effective Molecular Testing That Could Simplify MUC1 Variant Detection. Kidney Int Rep 2024; 9:1451-1457. [PMID: 38707821 PMCID: PMC11068942 DOI: 10.1016/j.ekir.2024.01.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 01/23/2024] [Accepted: 01/29/2024] [Indexed: 05/07/2024] Open
Abstract
Introduction Patients with autosomal dominant tubulointerstitial kidney disease (ADTKD) usually present with nonspecific progressive chronic kidney disease (CKD) with mild to negative proteinuria and a family history. ADTKD-MUC1 leads to the formation of a frameshift protein that accumulates in the cytoplasm, leading to tubulointerstitial damage. ADTKD-MUC1 prevalence remains unclear because MUC1 variants are not routinely detected by standard next-generation sequencing (NGS) techniques. Methods We developed a bioinformatic counting script that can detect specific genetic sequences and count the number of occurrences. We used DNA samples from 27 patients for validation, 11 of them were patients from the Lille University Hospital in France and 16 were from the Wake Forest Hospital, NC. All patients from Lille were tested with an NGS gene panel with our script and all patients from Wake Forest Hospital were tested with the snapshot reference technique. Between January 2018 and February 2023, we collected data on all patients diagnosed with MUC1 variants with this script. Results A total of 27 samples were tested anonymously by the BROAD Institute reference technique for confirmation and we were able to get a 100% concordance for MUC1 diagnosis. Clinico-biologic characteristics in our cohort were similar to those previously described in ADTKD-MUC1. Conclusion We describe a new simple and cost-effective method for molecular testing of ADTKD-MUC1. Genetic analyses in our cohort suggest that MUC1 might be the first cause of ADTKD. Increasing the availability of MUC1 diagnosis tools will contribute to a better understanding of the disease and to the development of specific treatments.
Collapse
Affiliation(s)
- Victor Fages
- Nephrology, Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Florentin Bourre
- Nephrology, Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Romain Larrue
- Service de Toxicologie et Génopathies, CHU Lille, Lille, France
| | - Andrea Wenzel
- Institute of Human Genetics, Center for Molecular Medicine Cologne, Cologne, Germany
| | | | - Fabrice Bonte
- Functional and Structural Platform, Université de Lille, Lille, France
| | - Claire-Marie Dhaenens
- Department of Biochemistry and Molecular Biology, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Kendrah Kidd
- Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Stanislav Kmoch
- First Faculty of Medicine, Charles University, Nové Město, Czechia
| | - Anthony Bleyer
- Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - François Glowacki
- Nephrology, Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Olivier Grunewald
- Neuroscience and Cognition, University Lille, Inserm, CHU Lille, Lille, France
| |
Collapse
|
2
|
Lionet A, Van Triempon M, Figeac M, Fages V, Gibier JB, Provot F, Maanaoui M, Pottier N, Cauffiez C, Glowacki F. Extracorporeal Photopheresis Reduces Fibrotic and Inflammatory Transcriptomic Biological Marker of Chronic Antibody-mediated Kidney Rejection. Transplant Direct 2024; 10:e1587. [PMID: 38380348 PMCID: PMC10876237 DOI: 10.1097/txd.0000000000001587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 11/27/2023] [Accepted: 12/06/2023] [Indexed: 02/22/2024] Open
Abstract
Background The benefit of extracorporeal photopheresis on the course of kidney transplant rejection is unknown. The aim of our study was to investigate the variations in transcriptomics on graft biopsies when extracorporeal photopheresis was used to treat chronic humoral rejection after kidney transplantation. Methods We retrospectively analyzed the mRNA expression of 770 genes of interest in graft biopsies performed before and after treatment. Eight patients received an average of 23 extracorporeal photopheresis sessions over 4 mo between the 2 biopsies. Results Transcriptomic analysis of the graft biopsies identified a significant (adjusted P < 0.05) increase in CAV1 mRNA in all patients and a significant decrease in CD19, IL21, PAX5, and SFTPA2 mRNAs in 7 of 8 patients. Conclusions In patients treated with extracorporeal photopheresis for chronic humoral rejection after renal transplantation, omic analysis of repeated biopsies shows a reduction in fibrotic and inflammatory transcriptomic biologicals markers.
Collapse
Affiliation(s)
- Arnaud Lionet
- Department of Nephrology and Kidney Transplantation, University Hospital Huriez, CHU-Lille, Lille, France
- CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277—CANTHER, University of Lille, Lille, France
| | - Marine Van Triempon
- Department of Nephrology and Kidney Transplantation, University Hospital Huriez, CHU-Lille, Lille, France
| | - Martin Figeac
- CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41—UAR 2014—PLBS, University of Lille, Lille, France
| | - Victor Fages
- Department of Nephrology and Kidney Transplantation, University Hospital Huriez, CHU-Lille, Lille, France
| | | | - François Provot
- Department of Nephrology and Kidney Transplantation, University Hospital Huriez, CHU-Lille, Lille, France
| | - Mehdi Maanaoui
- Department of Nephrology and Kidney Transplantation, University Hospital Huriez, CHU-Lille, Lille, France
- CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMRU1190 Translational Research for Diabetes, University of Lille, Lille, France
| | - Nicolas Pottier
- CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277—CANTHER, University of Lille, Lille, France
| | - Christelle Cauffiez
- CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277—CANTHER, University of Lille, Lille, France
| | - François Glowacki
- Department of Nephrology and Kidney Transplantation, University Hospital Huriez, CHU-Lille, Lille, France
- CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277—CANTHER, University of Lille, Lille, France
| |
Collapse
|
3
|
Fages V, Jannin A, Maanaoui M, Glowacki F, Do Cao C. Proteinuria reduction with SGLT2 inhibitors in a patient treated with tyrosine kinase inhibitor lenvatinib. J Nephrol 2024; 37:187-189. [PMID: 37418091 DOI: 10.1007/s40620-023-01701-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Accepted: 06/09/2023] [Indexed: 07/08/2023]
Abstract
We describe the case of a 66-year-old woman treated with tyrosine kinase inhibitor Lenvatinib for thyroid carcinoma who had persistent proteinuria above 2 g/24 h despite maximal dose of angiotensin-converting enzyme inhibitor. We initiated a treatment with SGLT2 inhibitor Dapagliflozin. Three months after Dapagliflozin initiation, her proteinuria decreased to 1 g/24 h, and after 6 months of follow-up was 0.6 g/24 h. To our knowledge, this is the first case of successful proteinuria reduction with SGLT2i in a patient treated with Lenvatinib. Specific renal effects of SGLT2i seem promising and their effects on tyrosine kinase inhibitor renal adverse effects need to be validated in clinical trials involving cancer patients.
Collapse
Affiliation(s)
- Victor Fages
- Service de Néphrologie, CHRU Lille, Hôpital Huriez, Rue Michel Polonowski, 59037, Lille, France.
| | - Arnaud Jannin
- Department of Diabetology, Endocrinology, Metabolism and Nutrition, Centre Hospitalier Regional Universitaire de Lille, Lille University Hospital, Lille, France
| | - Mehdi Maanaoui
- Service de Néphrologie, CHRU Lille, Hôpital Huriez, Rue Michel Polonowski, 59037, Lille, France
| | - François Glowacki
- Service de Néphrologie, CHRU Lille, Hôpital Huriez, Rue Michel Polonowski, 59037, Lille, France
| | - Christine Do Cao
- Department of Diabetology, Endocrinology, Metabolism and Nutrition, Centre Hospitalier Regional Universitaire de Lille, Lille University Hospital, Lille, France
| |
Collapse
|
4
|
Hamroun A, Glowacki F, Frimat L. Comprehensive conservative care: what doctors say, what patients hear. Nephrol Dial Transplant 2023; 38:2428-2443. [PMID: 37156527 DOI: 10.1093/ndt/gfad088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Indexed: 05/10/2023] Open
Abstract
The demographic evolution of patients with advanced chronic kidney disease (CKD) has led to the advent of an alternative treatment option to kidney replacement therapy in the past couple of decades. The KDIGO controversies on Kidney Supportive Care called this approach "comprehensive conservative care" (CCC) and defined it as planned holistic patient-centered care for patients with CKD stage 5 that does not include dialysis. Although the benefit of this treatment option is now well-recognized, especially for the elderly, and comorbid and frail patients, its development remains limited in practice. While shared decision-making and advance care planning represent the cornerstones of the CCC approach, one of the main barriers in its development is the perfectible communication between nephrologists and patients, but also between all healthcare professionals involved in the care of advanced CKD patients. As a result, a significant gap has opened up between what doctors say and what patients hear. Indeed, although CCC is reported by nephrologists to be widely available in their facilities, few of their patients say that they have actually heard of it. The objectives of this review are to explore discrepancies between what doctors say and what patients hear, to identify the factors underlying this gap, and to formulate practical proposals for narrowing this gap in practice.
Collapse
Affiliation(s)
- Aghiles Hamroun
- Lille University, Lille University Hospital Center of Lille, Department of Nephrology, Dialysis, Kidney Transplantation, and Apheresis, Lille, France
- University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR1167 RID-AGE, F-59000 Lille, France
| | - François Glowacki
- Lille University, Lille University Hospital Center of Lille, Department of Nephrology, Dialysis, Kidney Transplantation, and Apheresis, Lille, France
- University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Luc Frimat
- Department of Nephrology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
- Inserm, CIC-1433 Clinical Epidemiology, University Hospital of Nancy, Université de Lorraine, Vandœuvre-Lès-Nancy, France
| |
Collapse
|
5
|
Fages V, Decaestecker A, Lessore C, Gaillard V, Odou MF, Lemaitre M, Glowacki F, Lionet A. A Pregnant Woman With Hypercalcemia-Induced Acute Pancreatitis. Kidney Int Rep 2023; 8:1680-1682. [PMID: 37547533 PMCID: PMC10403647 DOI: 10.1016/j.ekir.2023.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 05/07/2023] [Accepted: 05/08/2023] [Indexed: 08/08/2023] Open
Affiliation(s)
- Victor Fages
- Centre Hospitalier Regional Universitaire de Lille, Nephrology, Lille, France
| | | | - Célia Lessore
- Centre Hospitalier Regional Universitaire de Lille, Nephrology, Lille, France
| | - Vianney Gaillard
- Centre Hospitalier Regional Universitaire de Lille, Department of Radiology, Lille, France
| | - Marie-Françoise Odou
- Centre Hospitalier Regional Universitaire de Lille, Service de Biochimie et Biologie moléculaire ‘Hormonologie, Métabolisme-Nutrition, Oncologie’, Lille, France
- Universite de Lille, Inserm, U1286 – Infinite – Institute for Translational Research in Inflammation, Lille, France
| | - Madleen Lemaitre
- Centre Hospitalier Regional Universitaire de Lille, Department of Diabetology, Endocrinology, Metabolism and Nutrition, Lille University Hospital, Lille, France
| | - François Glowacki
- Centre Hospitalier Regional Universitaire de Lille, Nephrology, Lille, France
| | - Arnaud Lionet
- Centre Hospitalier Regional Universitaire de Lille, Nephrology, Lille, France
| |
Collapse
|
6
|
Hamroun A, Glowacki F. Comprehensive conservative care for the management of advanced chronic kidney disease: overview and perspectives. Nephrol Ther 2023; 19:1-9. [PMID: 37305992 DOI: 10.1684/ndt.2023.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Comprehensive “conservative care” is defined as any active therapeutic procedure for the management of stage 5 chronic kidney disease without recourse to dialysis. This therapeutic option is discussed in elderly, frail patients whose anticipated life expectancy is reduced with dialysis. The decision for conservative management primarily relies on an informed choice by the patient and his caregivers. This holistic approach, focused on quality of life, requires a multidisciplinary approach. The goals are to slow the progression of kidney disease, prevent complications, anticipate the risks of decompensation, provide support for the patient and his caregivers to maintain the best possible quality of life at home. This article describes the principles of conservative management, highlights various barriers to this care pathway, and proposes potential solutions.
Collapse
Affiliation(s)
- Aghiles Hamroun
- CHU de Lille, service de santé publique, épidémiologie, économie de la santé et prévention, Lille, France
- UMR1167 RID-AGE, Inserm, Institut Pasteur de Lille, Université de Lille, CHU de Lille, France
| | - François Glowacki
- CHU de Lille, service de néphrologie, dialyse, transplantation rénale et aphérère, Lille, France
- UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, CNRS, Inserm, CHU de Lille, France
| |
Collapse
|
7
|
Laboux T, Maanaoui M, Allain F, Boulanger E, Denys A, Gibier JB, Glowacki F, Grolaux G, Grunenwald A, Howsam M, Lancel S, Lebas C, Lopez B, Roumenina L, Provôt F, Gnemmi V, Frimat M. Hemolysis is associated with altered heparan sulfate of the endothelial glycocalyx and with local complement activation in thrombotic microangiopathies. Kidney Int 2023:S0085-2538(23)00327-7. [PMID: 37164260 DOI: 10.1016/j.kint.2023.03.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2022] [Revised: 03/03/2023] [Accepted: 03/24/2023] [Indexed: 05/12/2023]
Abstract
The complement system plays a key role in the pathophysiology of kidney thrombotic microangiopathies (TMA), as illustrated by atypical hemolytic uremic syndrome. But complement abnormalities are not the only drivers of TMA lesions. Among other potential pathophysiological actors, we hypothesized that alteration of heparan sulfate (HS) in the endothelial glycocalyx could be important. To evaluate this, we analyzed clinical and histological features of kidney biopsies from a monocentric, retrospective cohort of 72 patients with TMA, particularly for HS integrity and markers of local complement activation. The role of heme (a major product of hemolysis) as an HS-degrading agent in vitro, and the impact of altering endothelial cell (ECs) HS on their ability to locally activate complement were studied. Compared with a positive control, glomerular HS staining was lower in 57 (79%) patients with TMA, moderately reduced in 20 (28%), and strongly reduced in 37 (51%) of these 57 cases. Strongly reduced HS density was significantly associated with both hemolysis at the time of biopsy and local complement activation (C3 and/or C5b-9 deposits). Using primary endothelial cells (HUVECs, Glomerular ECs), we observed decreased HS expression after short-term exposure to heme, and that artificial HS degradation by exposure to heparinase was associated with local complement activation. Further, prolonged exposure to heme modulated expression of several key genes of glycocalyx metabolism involved in coagulation regulation (C5-EPI, HS6ST1, HS3ST1). Thus, our study highlights the impact of hemolysis on the integrity of endothelial HS, both in patients and in endothelial cell models. Hence, acute alteration of HS may be a mechanism of heme-induced complement activation.
Collapse
Affiliation(s)
- Timothée Laboux
- University Lille, CHU Lille, Nephrology Department, Lille, France; University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France.
| | - Mehdi Maanaoui
- University Lille, CHU Lille, Nephrology Department, Lille, France; University Lille, Inserm, Institut Pasteur de Lille, U1190 - EGID, Lille, France
| | | | - Eric Boulanger
- University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France
| | - Agnès Denys
- University Lille, CNRS, UMR 8576 - UGSF, Lille, France
| | - Jean-Baptiste Gibier
- Univ. Lille, Pathology Department, F-59000, Lille, France; University Lille, Inserm, US1172, Lille, France
| | | | - Gaëlle Grolaux
- University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France
| | - Anne Grunenwald
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France
| | - Mike Howsam
- University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France
| | - Steve Lancel
- University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France
| | - Céline Lebas
- University Lille, CHU Lille, Nephrology Department, Lille, France
| | | | - Lubka Roumenina
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France
| | - François Provôt
- University Lille, CHU Lille, Nephrology Department, Lille, France
| | - Viviane Gnemmi
- Univ. Lille, Pathology Department, F-59000, Lille, France; University Lille, CNRS, Inserm, U9020-UMR-S 1277, Lille, France
| | - Marie Frimat
- University Lille, CHU Lille, Nephrology Department, Lille, France; University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France.
| |
Collapse
|
8
|
Hamroun A, Speyer E, Ayav C, Combe C, Fouque D, Jacquelinet C, Laville M, Liabeuf S, Massy ZA, Pecoits-Filho R, Robinson BM, Glowacki F, Stengel B, Frimat L. Barriers to conservative care from patients' and nephrologists' perspectives: the CKD-REIN study. Nephrol Dial Transplant 2022; 37:2438-2448. [PMID: 35026014 DOI: 10.1093/ndt/gfac009] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Conservative care is increasingly considered an alternative to kidney replacement therapy for kidney failure management, mostly among the elderly. We investigated its status and the barriers to its implementation from patients' and providers' perspectives. METHODS We analysed data from 1204 patients with advanced chronic kidney disease (CKD) [estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2] enrolled at 40 nationally representative nephrology clinics (2013-16) who completed a self-administered questionnaire about the information they received and their preferred treatment option, including conservative care, if their kidneys failed. Nephrologists (n = 137) also reported data about their clinics' resources and practices regarding conservative care. RESULTS All participating facilities reported they were routinely able to offer conservative care, but only 37% had written protocols and only 5% had a person or team primarily responsible for it. Overall, 6% of patients were estimated to use conservative care. Among nephrologists, 82% reported they were fairly or extremely comfortable discussing conservative care, but only 28% usually or always offered this option for older (>75 years) patients approaching kidney failure. They used various terminology for this care, with conservative management and non-dialysis care mentioned most often. Among patients, 5% of those >75 years reported receiving information about this option and 2% preferring it. CONCLUSIONS Although reported by nephrologists to be widely available and easily discussed, conservative care is only occasionally offered to older patients, most of whom report they were not informed of this option. The lack of a person or team responsible for conservative care and unclear information appear to be key barriers to its implementation.
Collapse
Affiliation(s)
- Aghilès Hamroun
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Équipe Epidémiologie Clinique, CESP, Villejuif, France.,Lille University, University Hospital of Lille, Nephrology Department, Lille, France
| | - Elodie Speyer
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Équipe Epidémiologie Clinique, CESP, Villejuif, France
| | - Carole Ayav
- CHRU-Nancy, INSERM, CIC 1433, Epidémiologie Clinique, Nancy, France
| | - Christian Combe
- Service de Néphrologie Transplantation Dialyse Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.,Inserm U1026, Université de Bordeaux, Bordeaux, France
| | - Denis Fouque
- Service de Néphrologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.,Université Claude Bernard Lyon 1, Carmen INSERM U1060, Pierre-Bénite, France
| | | | - Maurice Laville
- Université Claude Bernard Lyon 1, Carmen INSERM U1060, Pierre-Bénite, France
| | - Sophie Liabeuf
- Service de Pharmacologie Clinique, Département de recherche clinique CHU Amiens-Picardie, Amiens, France.,Laboratoire MP3CV, EA7517, Université de Picardie Jules Verne, Amiens, France
| | - Ziad A Massy
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Équipe Epidémiologie Clinique, CESP, Villejuif, France.,Service de néphrologie, Hôpital Ambroise Paré, AP-HP, Boulogne-Billancourt, France
| | | | | | - François Glowacki
- Lille University, University Hospital of Lille, Nephrology Department, Lille, France
| | - Bénédicte Stengel
- Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Équipe Epidémiologie Clinique, CESP, Villejuif, France
| | - Luc Frimat
- Service de Néphrologie, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.,Université de Lorraine, APEMAC, Nancy, France
| | | |
Collapse
|
9
|
Larrue R, Fellah S, Van der Hauwaert C, Hennino MF, Perrais M, Lionet A, Glowacki F, Pottier N, Cauffiez C. The Versatile Role of miR-21 in Renal Homeostasis and Diseases. Cells 2022; 11:cells11213525. [PMID: 36359921 PMCID: PMC9657972 DOI: 10.3390/cells11213525] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 11/03/2022] [Accepted: 11/04/2022] [Indexed: 11/09/2022] Open
Abstract
MicroRNAs (miRNAs) are small, non-coding RNA species that control gene expression and confer robustness to biological processes. Over the last two decades, their important roles during kidney development, homeostasis and the treatment of diseases have been established, in particular during the onset and progression of various forms of acute and chronic renal disorders. In recent years, miR-21, one of the best-characterized miRNAs to date, has received much attention in renal physiology in particular given its high degree of conservation and expression in kidneys, as well as its potent pathogenic role in various debilitating renal diseases. This review summarizes the current knowledge on miR-21’s involvement in both renal homeostasis and diseases, in particular its double-edged-sword role in acute versus chronic kidney injuries. Finally, we also discuss the potential of miR-21 as a biomarker and therapeutic target in renal diseases.
Collapse
Affiliation(s)
- Romain Larrue
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Sandy Fellah
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Cynthia Van der Hauwaert
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
- CHU Lille, Département de la Recherche en Santé, F-59000 Lille, France
| | | | - Michaël Perrais
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Arnaud Lionet
- CHU Lille, Service de Néphrologie, F-59000 Lille, France
| | - François Glowacki
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
- CHU Lille, Service de Néphrologie, F-59000 Lille, France
| | - Nicolas Pottier
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Christelle Cauffiez
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277—CANTHER—Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
- Correspondence:
| |
Collapse
|
10
|
El Karoui K, Hourmant M, Ayav C, Glowacki F, Couchoud C, Lapidus N. Vaccination and COVID-19 Dynamics in Dialysis Patients. Clin J Am Soc Nephrol 2022; 17:395-402. [PMID: 35144970 PMCID: PMC8975027 DOI: 10.2215/cjn.10300721] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Accepted: 01/10/2022] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND OBJECTIVES Dialysis patients have a high mortality risk after coronavirus disease 2019 (COVID-19) and an altered immunologic response to vaccines, but vaccine clinical effectiveness remains unknown in this population. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Using Bayesian multivariable spatiotemporal models, we estimated the association between vaccine exposure and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severe infections (with hospital admission) in dialysis patients from simultaneous incidence in the general population. For dialysis patients, cases were reported within the French end-stage kidney disease REIN registry from March 11, 2020, to April 29, 2021, and vaccine exposure (first dose) was reported in weekly national surveys since January 2021. Cases in the general population were obtained from the national exhaustive inpatient surveillance system (SI-VIC database), and vaccination coverage (first dose) was obtained from the national surveillance system (VAC-SI database). RESULTS During the first wave, incidence in dialysis patients was approximately proportional to the general population. However, we showed a lower relative incidence for dialysis patients during the second wave (compared with that observed in nondialysis patients), suggesting an effect of prevention measures. Moreover, from the beginning of the vaccination rollout, incidence in dialysis patients was lower compared with predictions based on the first and second waves. Adding vaccination coverages in dialysis and nondialysis patients as predictors allowed the reported cases to be fit correctly (3685 predicted cases, 95% confidence interval, 3552 to 3816, versus 3620 reported). Incidence rate ratios were 0.37 (95% confidence interval, 0.18 to 0.71) for vaccine exposure in dialysis patients and 0.50 (95% confidence interval, 0.40 to 0.61) per 10% higher in vaccination coverage in the same-age general population, meaning that vaccine exposure in dialysis patients and the general population was independently associated with lower hospitalization rate of dialysis patients. CONCLUSIONS Our findings suggest that vaccination may yield a protective effect against severe forms of COVID-19 in dialysis patients, despite altered immunologic vaccine responses.
Collapse
Affiliation(s)
- Khalil El Karoui
- Assistance Publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare "Syndrome Néphrotique Idiopathique," Fédération Hospitalo-Universitaire "Innovative therapy for immune disorders," Créteil, France .,Univ Paris Est Créteil, INSERM U955, Institut Mondor de Recherche Biomédicale (IMRB), Equipe 21, Créteil, France
| | | | - Carole Ayav
- REIN Registry, Agence de la biomédecine, Saint-Denis La Plaine, France,CHRU-Nancy, INSERM, Université de Lorraine, CIC, Epidémiologie Clinique, F-54000, Nancy, France
| | - François Glowacki
- REIN Registry, Agence de la biomédecine, Saint-Denis La Plaine, France,Univ. Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France,CNRS, UMR9020, F-59000, Lille, France,INSERM, U1277, F-59000, Lille, France,CHU Lille, Service de Nephrologie, F-59000, Lille, France
| | - Cécile Couchoud
- REIN Registry, Agence de la biomédecine, Saint-Denis La Plaine, France
| | - Nathanaël Lapidus
- Assistance Publique Hôpitaux de Paris (AP-HP), Public Health Department, Saint-Antoine Hospital, Paris, France,Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique IPLESP, AP-HP, Sorbonne Université, Paris, France
| | | |
Collapse
|
11
|
Zaworski J, Gnemmi V, Bataille P, Hachulla E, Glowacki F, Gibier JB, Daroux M, Ratsimbazafy A, Bitton L, Humez S, Guincestre T, Béhal H, Azar R, Hoffmann M, Cardon G, Bourdon F, Lemoine C, Auxenfant E, Copin MC, Vandenbussche C, Quéméneur T. Early Renal Recovery after the First Flare of Pauci-Immune Glomerulonephritis. Am J Nephrol 2022; 53:59-68. [PMID: 35038711 DOI: 10.1159/000520285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Accepted: 09/30/2021] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Renal involvement is a severe manifestation of antineutrophil cytoplasmic antibody-associated vasculitis. Patients often progress to end-stage renal disease. The potential for renal recovery after the first flare has seldom been studied. Our objectives were to describe the evolution of the estimated glomerular filtration rate (eGFR) and identify factors associated with the change in the eGFR between diagnosis and the follow-up at 3 months (ΔeGFRM0-M3). METHODS This was a retrospective study over the period 2003-2018 of incident patients in the Nord-Pas-de-Calais (France). The primary outcome was the ΔeGFRM0-M3. RESULTS One hundred and seventy-seven patients were included. The eGFR at 3 months was significantly higher than at diagnosis (mean ± standard deviation, 40 ± 24 vs. 28 ± 26 mL/min/1.73 m2, p < 0.001), with a ΔeGFRM0-M3 of 12 ± 19 mL/min/1.73 m2. The eGFR at 12 months was higher than at 3 months (44 ± 13 vs. 40 ± 24 mL/min/1.73 m2, p = 0.003). The factors significantly associated with the ΔeGFRM0-M3 in multivariate analysis were the percentage of cellular crescents and neurological involvement. The mean increase in the eGFR was 2.90 ± 0.06 mL/min/1.73 m2 for every 10-point gain in the percentage of cellular crescents. CONCLUSIONS Early renal recovery after the first flare of pauci-immune glomerulonephritis occurred mainly in the first 3 months of treatment. The percentage of cellular crescents was the main independent predictor of early renal recovery.
Collapse
Affiliation(s)
- Jérémy Zaworski
- Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France
| | - Viviane Gnemmi
- Department of Pathology, Pathology Institute, Lille University Hospital (CHU), Lille, France
| | - Pierre Bataille
- Department of Nephrology, Hospital of Boulogne-Sur-Mer, Boulogne-sur-Mer, France
| | - Eric Hachulla
- Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, Lille, France
| | | | - Jean-Baptiste Gibier
- Department of Pathology, Pathology Institute, Lille University Hospital (CHU), Lille, France
| | - Maïté Daroux
- Department of Nephrology, Hospital of Boulogne-Sur-Mer, Boulogne-sur-Mer, France
| | | | - Laura Bitton
- Department of Pathology, Pathology Institute, Lille University Hospital (CHU), Lille, France
| | - Sarah Humez
- Department of Pathology, Pathology Institute, Lille University Hospital (CHU), Lille, France
| | | | - Hélène Béhal
- Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France
| | - Raymond Azar
- Department of Nephrology, Hospital of Dunkerque, Dunkerque, France
| | - Maxime Hoffmann
- Department of Nephrology, Hôpital Privé La Louvière de Lille, Lille, France
| | | | - Franck Bourdon
- Department of Nephrology, Clinique du Bois, Lille, France
| | - Corinne Lemoine
- Department of Nephrology, Clinique privé de Bois-Bernard, Bois-Bernard, France
| | - Eric Auxenfant
- Department of Internal Medicine, Centre Hospitalier de Roubaix, Roubaix, France
| | - Marie-Christine Copin
- Department of Pathology, Pathology Institute, Lille University Hospital (CHU), Lille, France
| | - Cyrille Vandenbussche
- Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France
| | - Thomas Quéméneur
- Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France
| |
Collapse
|
12
|
Maanaoui M, Baes D, Hamroun A, Khedjat K, Vuotto F, Faure E, Lopez B, Bouyé S, Caes T, Lionet A, Lebas C, Provôt F, Glowacki F, Gibier JB, Lenain R, Hazzan M. Association between acute graft pyelonephritis and kidney graft survival: A single-center observational study. Am J Transplant 2021; 21:3640-3648. [PMID: 34057805 DOI: 10.1111/ajt.16703] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 04/29/2021] [Accepted: 05/18/2021] [Indexed: 01/25/2023]
Abstract
The association between acute graft pyelonephritis (AGPN) and graft failure in kidney transplant recipients (KTR) remains controversial. In this single-center observational study, we aimed to assess the incidence of AGPN as a time-dependent posttransplantation event. We also examined the association between the diagnosis of AGPN and graft outcomes. In total, we evaluated 1480 patients who underwent kidney transplantation between January 2007 and December 2017. During a median follow-up of 5.04 years, we observed 297 AGPN episodes that occurred in 158 KTR. To evaluate the association between AGPN and clinical outcomes, we performed Cox proportional hazards regression analyses in which AGPN was entered as a time-dependent covariate. AGPN was independently associated with an increased risk of graft loss (hazard ratio = 1.66; 95% confidence interval [CI]: 1.05-2.64, p < .03) and a persistently decreased eGFR (fixed effect on intercept: -2.29 ml/min/1.73 m2 ; 95% CI: from -3.23 to -1.35, p < .01). However, neither mortality nor biopsy-proven acute rejection was found to correlate with AGPN. Moreover, recurrent AGPN episodes did not appear to have an additive detrimental impact on graft loss. These data represent a promising step in understanding whether AGPN prevention may decrease the risk of graft loss in KTR.
Collapse
Affiliation(s)
- Mehdi Maanaoui
- Department of Nephrology, CHU Lille, Lille, France.,Université de Lille, Inserm, CHU Lille, Institut Pasteur Lille, Lille, France
| | | | - Aghilès Hamroun
- Department of Nephrology, CHU Lille, Lille, France.,Clinical Epidemiology Team, CESP, Center for Research in Epidemiology and Population Health, Inserm, Paris-Saclay University, Versailles Saint Quentin University, Villejuif, France
| | | | - Fanny Vuotto
- Service de Maladies Infectieuses, CHU Lille, Lille, France
| | - Emmanuel Faure
- Service de Maladies Infectieuses, CHU Lille, Lille, France
| | - Benjamin Lopez
- Laboratoire de Biologie Médicale, CH Dunkerque, Dunkerque, France
| | | | - Thomas Caes
- Department of Urology, CHU Lille, Lille, France
| | | | - Céline Lebas
- Department of Nephrology, CHU Lille, Lille, France
| | | | | | - Jean-Baptiste Gibier
- Department of Pathology, Pathology Institute, Regional and University Hospital Center of Lille, Inserm UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team "Mucins, Epithelial Differentiation and Carcinogenesis", Lille University, Lille, France
| | - Rémi Lenain
- Department of Nephrology, CHU Lille, Lille, France
| | - Marc Hazzan
- Department of Nephrology, CHU Lille, Lille, France
| |
Collapse
|
13
|
Lenain R, Maanaoui M, Hamroun A, Larrue R, Van Der Hauwaert C, Gibier JB, Gnemmi V, Gomis S, Labalette M, Broly F, Hennart B, Pottier N, Hazzan M, Cauffiez C, Glowacki F. Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study. J Pers Med 2021; 11:jpm11101002. [PMID: 34683143 PMCID: PMC8539387 DOI: 10.3390/jpm11101002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 09/25/2021] [Accepted: 09/30/2021] [Indexed: 11/24/2022] Open
Abstract
The pharmacokinetic variability of tacrolimus can be partly explained by CYP3A5 activity. Our objective was to evaluate a tacrolimus sparing policy on renal graft outcome according to CYP3A5 6986A>G genetic polymorphism. This retrospective study included 1114 recipients with a median follow-up of 6.3 years. Genotyping of the 6986A>G allelic variant corresponding to CYP3A5*3 was systematically performed. One year after transplantation, tacrolimus blood trough concentration (C0) target range was 5–7 ng/mL. However, daily dose was capped to 0.10 mg/kg/day regardless of the CYP3A5 genotype. A total 208 CYP3A5*1/- patients were included. Despite a higher daily dose, CYP3A5*1/- recipients exhibited lower C0 during follow-up (p < 0.01). Multivariate analysis did not show any significant influence of CYP3A5*1/- genotype (HR = 0.70, 0.46–1.07, p = 0.10) on patient-graft survival. Glomerular Filtration Rate (GFR) decline was significantly lower for the CYP3A5*1/- group (p = 0.02). The CYP3A5*1/- genotype did not significantly impact the risk of biopsy-proven acute rejection (BPAR) (HR = 1.01, 0.68–1.49, p = 0.97) despite significantly lower C0. Based on our experience, a strategy of tacrolimus capping is associated with a better GFR evolution in CYP3A5*1/- recipients without any significant increase of BPAR incidence. Our study raised some issues about specific therapeutic tacrolimus C0 targets for CYP3A5*1/- patients and suggests to set up randomized control studies in this specific population.
Collapse
Affiliation(s)
- Rémi Lenain
- CHU Lille, Service de Néphrologie, F-59000 Lille, France; (R.L.); (M.M.); (A.H.); (S.G.); (M.H.); (F.G.)
| | - Mehdi Maanaoui
- CHU Lille, Service de Néphrologie, F-59000 Lille, France; (R.L.); (M.M.); (A.H.); (S.G.); (M.H.); (F.G.)
| | - Aghilès Hamroun
- CHU Lille, Service de Néphrologie, F-59000 Lille, France; (R.L.); (M.M.); (A.H.); (S.G.); (M.H.); (F.G.)
| | - Romain Larrue
- UMR9020-U1277—CANTHER—Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (R.L.); (C.V.D.H.); (N.P.)
- CHU Lille, Service de Toxicologie et Génopathies, F-59000 Lille, France; (F.B.); (B.H.)
| | - Cynthia Van Der Hauwaert
- UMR9020-U1277—CANTHER—Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (R.L.); (C.V.D.H.); (N.P.)
- CHU Lille, Département de la Recherche en Santé, F-59000 Lille, France
| | - Jean-Baptiste Gibier
- CHU Lille, Service d’Anatomo-Pathologie, F-59000 Lille, France; (J.-B.G.); (V.G.)
| | - Viviane Gnemmi
- CHU Lille, Service d’Anatomo-Pathologie, F-59000 Lille, France; (J.-B.G.); (V.G.)
| | - Sébastien Gomis
- CHU Lille, Service de Néphrologie, F-59000 Lille, France; (R.L.); (M.M.); (A.H.); (S.G.); (M.H.); (F.G.)
| | - Myriam Labalette
- CHU de Lille, Institut D’Immunologie-HLA, F-59000 Lille, France;
| | - Franck Broly
- CHU Lille, Service de Toxicologie et Génopathies, F-59000 Lille, France; (F.B.); (B.H.)
| | - Benjamin Hennart
- CHU Lille, Service de Toxicologie et Génopathies, F-59000 Lille, France; (F.B.); (B.H.)
| | - Nicolas Pottier
- UMR9020-U1277—CANTHER—Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (R.L.); (C.V.D.H.); (N.P.)
- CHU Lille, Service de Toxicologie et Génopathies, F-59000 Lille, France; (F.B.); (B.H.)
| | - Marc Hazzan
- CHU Lille, Service de Néphrologie, F-59000 Lille, France; (R.L.); (M.M.); (A.H.); (S.G.); (M.H.); (F.G.)
| | - Christelle Cauffiez
- UMR9020-U1277—CANTHER—Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (R.L.); (C.V.D.H.); (N.P.)
- Correspondence:
| | - François Glowacki
- CHU Lille, Service de Néphrologie, F-59000 Lille, France; (R.L.); (M.M.); (A.H.); (S.G.); (M.H.); (F.G.)
- UMR9020-U1277—CANTHER—Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (R.L.); (C.V.D.H.); (N.P.)
| |
Collapse
|
14
|
Hamroun A, Frimat L, Laville M, Metzger M, Combe C, Fouque D, Jacquelinet C, Ayav C, Liabeuf S, Lange C, Herpe YE, Zee J, Glowacki F, Massy ZA, Robinson B, Stengel B. New Insights into Acute-on-Chronic Kidney Disease in Nephrology Patients: The CKD-REIN Study. Nephrol Dial Transplant 2021; 37:1700-1709. [PMID: 34473306 DOI: 10.1093/ndt/gfab249] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Acute-on-chronic kidney disease (ACKD) is poorly understood and often overlooked. We studied its incidence, circumstances, determinants, and outcomes in patients with CKD. METHODS We used the Kidney Disease Improving Global Outcomes criteria to identify all-stage acute kidney injury (AKI) events in 3033 nephrology outpatients with CKD stage 3-5 participating in the CKD-REIN cohort study (2013-2020), and cause-specific Cox models to estimate hazard ratios (HR, 95% confidence intervals [CI]) of AKI-associated risk factors. RESULTS At baseline, 22% of the patients (mean age 67 years, 65% men, mean eGFR 32 ml/min/1.73m2) had a history of AKI. Over a 3-year follow-up, 443 had at least one AKI event: 27% were stage 2 or 3, and 11% required dialysis; 74% involved hospitalization including 47% acquired as hospital inpatients; a third were not reported in hospital discharge reports. Incidence rates were 10.1 and 4.8 per 100 person-years in patients with and without an AKI history, respectively. In 2375 patients without this history, male sex, diabetes, cardiovascular disease, cirrhosis, several drugs, low eGFR, and serum albumin levels were significantly associated with a higher risk of AKI, as were low birth weight (<2500 g) (adjusted HR, 1.98; 95%CI, 1.35 to 2.91) and hemoglobin level (HR 1.21; 1.12 to 1.32 per 1 g/dl decrease). Within one year, only 63% of the patients had recovered their previous kidney function, 13.7% had started kidney replacement therapy, and 12.7% had died. CONCLUSIONS The study highlights the high rate of hospital-acquired AKI events in patients with CKD, and their underreporting at hospital discharge. It also reveals low birth weight and anemia as possible new risk factors in CKD patients.
Collapse
Affiliation(s)
- Aghilès Hamroun
- Paris-Saclay University, Versailles Saint Quentin University, Inserm, Clinical Epidemiology Team, CESP, Centre for Research in Epidemiology and Population Health, F-94807 Villejuif, France.,Department of Nephrology, Dialysis, and Transplantion, Regional University Hospital Centre of Lille, F-59037 Lille, France
| | - Luc Frimat
- Department of Nephrology, Nancy University Hospital, F-54000 Vandoeuvre-lès-Nancy, France.,Lorraine University, APEMAC, F-54000 Nancy, France
| | - Maurice Laville
- Department of Nephrology, Lyon Sud Hospital, F-69495 Pierre Bénite, France.,Lyon University, INSERM U1060, CarMeN, F-69495 Pierre Bénite, France
| | - Marie Metzger
- Paris-Saclay University, Versailles Saint Quentin University, Inserm, Clinical Epidemiology Team, CESP, Centre for Research in Epidemiology and Population Health, F-94807 Villejuif, France
| | - Christian Combe
- Nephrology Transplantation, Dialysis, Bordeaux University Hospital, F-33076 Bordeaux, France.,Inserm U1026, Bordeaux Segalen University, F-33076 Bordeaux, France
| | - Denis Fouque
- Department of Nephrology, Lyon Sud Hospital, F-69495 Pierre Bénite, France.,Lyon University, INSERM U1060, CarMeN, F-69495 Pierre Bénite, France
| | | | - Carole Ayav
- Department of Clinical Epidemiology, INSERM CIC-EC 1433, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
| | - Sophie Liabeuf
- Amiens University Hospital, Clinical Research Centre, Avenue R.Laennec, AMIENS, Picardie, FR 80000
| | - Céline Lange
- Agence de la Biomédecine, La Plaine Saint-Denis, France
| | | | - Jarcy Zee
- Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
| | - François Glowacki
- Department of Nephrology, Dialysis, and Transplantion, Regional University Hospital Centre of Lille, F-59037 Lille, France
| | - Ziad A Massy
- Paris-Saclay University, Versailles Saint Quentin University, Inserm, Clinical Epidemiology Team, CESP, Centre for Research in Epidemiology and Population Health, F-94807 Villejuif, France.,Department of Nephrology, Ambroise Paré University Hospital, Boulogne-Billancourt, Paris, France
| | - Bruce Robinson
- Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
| | - Bénédicte Stengel
- Paris-Saclay University, Versailles Saint Quentin University, Inserm, Clinical Epidemiology Team, CESP, Centre for Research in Epidemiology and Population Health, F-94807 Villejuif, France
| | | |
Collapse
|
15
|
Hamroun A, Bui L, Gomis S, Sarraj A, Choukroun G, Glowacki F. Lien entre le DFG estimé à l’initiation de la dialyse et la mortalité chez les patients incidents de 75 ans et plus. Nephrol Ther 2021. [DOI: 10.1016/j.nephro.2021.07.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Laboux T, Gibier JB, Pottier N, Glowacki F, Hamroun A. Correction to: COVID-19-related collapsing glomerulopathy revealing a rare risk variant of APOL1: lessons for the clinical nephrologist. J Nephrol 2021; 34:379. [PMID: 33811605 PMCID: PMC8019289 DOI: 10.1007/s40620-021-01037-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Timothée Laboux
- Kidney Transplantation and Dialysis Department, University of Lille, CHU Lille, 59037, Lille, France.
- RID-AGE, INSERM U1167, 59000, Lille, France.
| | - Jean-Baptiste Gibier
- Department of Pathology, Pathology Institute, Lille University, Regional and University Hospital Center of Lille, Lille, France
- INSERM UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team Mucins, Epithelial Differentiation and Carcinogenesis, 59037, Lille, France
| | - Nicolas Pottier
- Toxicology and Genopathy Department, CHU Lille, 59000, Lille, France
- INSERM U1190, Translational Research for Diabetes, Lille, France
| | - François Glowacki
- Kidney Transplantation and Dialysis Department, University of Lille, CHU Lille, 59037, Lille, France
- CNRS, INSERM, Lille University, UMR9020- UMR-S 1277, F-59000, Lille, France
| | - Aghilès Hamroun
- Kidney Transplantation and Dialysis Department, University of Lille, CHU Lille, 59037, Lille, France
- Clinical Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM, Paris-Saclay University, Versailles Saint-Quentin University, CESP, 94807, Villejuif, France
| |
Collapse
|
17
|
Laboux T, Gibier JB, Pottier N, Glowacki F, Hamroun A. COVID-19-related collapsing glomerulopathy revealing a rare risk variant of APOL1: lessons for the clinical nephrologist. J Nephrol 2021; 34:373-378. [PMID: 33548053 PMCID: PMC7865108 DOI: 10.1007/s40620-020-00935-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 11/20/2020] [Indexed: 12/14/2022]
Affiliation(s)
- Timothée Laboux
- Kidney Transplantation and Dialysis Department, University of Lille, CHU Lille, 59037, Lille, France.
- RID-AGE, INSERM U1167, 59000, Lille, France.
| | - Jean-Baptiste Gibier
- Department of Pathology, Pathology Institute, Lille University, Regional and University Hospital Center of Lille, Lille, France
- INSERM UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team Mucins, Epithelial Differentiation and Carcinogenesis, 59037, Lille, France
| | - Nicolas Pottier
- Toxicology and Genopathy Department, CHU Lille, 59000, Lille, France
- INSERM U1190, Translational Research for Diabetes, Lille, France
| | - François Glowacki
- Kidney Transplantation and Dialysis Department, University of Lille, CHU Lille, 59037, Lille, France
- CNRS, INSERM, Lille University, UMR9020- UMR-S 1277, F-59000, Lille, France
| | - Aghilès Hamroun
- Kidney Transplantation and Dialysis Department, University of Lille, CHU Lille, 59037, Lille, France
- Clinical Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM, Paris-Saclay University, Versailles Saint-Quentin University, CESP, 94807, Villejuif, France
| |
Collapse
|
18
|
Abstract
INTRODUCTION Chronic kidney disease is a serious and a frequent disease associated with a high risk of morbi-mortality. Although several risk factors have already been well addressed, mostly diabetes and hypertension, many remain underappreciated, such as chronic exposure to air pollution. METHODS AND ANALYSIS We will search EMBASE, PubMed, Web of Science, Cochrane Library and CINAHL database, from inception to 31 March 2020, for relevant records using a combination of keywords related to the type of exposure (ozone, carbon monoxide, nitrogen oxides and dioxide, sulfur dioxide, PM2.5, PMcoarse and PM10) and to the type of outcome (chronic kidney disease, end-stage renal/kidney disease, kidney failure, proteinuria/albuminuria, renal function, renal transplant, kidney graft, kidney transplant failure, nephrotic syndrome and kidney cancer). The review will be reported according to the guidelines of the Meta-analysis Of Observational Studies in Epidemiology. Two independent reviewers will select studies without design or language restrictions, using original data and investigating the association between exposure to one or more of the prespecified air pollutants and subsequent risk of renal outcomes. Using random-effects meta-analyses, we will present pooled summary statistics (HR, OR or beta-coefficients with their respective 95% CI) associated with a standardised increase in each pollutant level. The results will be presented by air pollutant and outcome. Heterogeneity will be assessed using the χ2 test on Cochran's Q statistic and quantified by calculating I2. The Egger's test and visual inspection of funnel plots will be used to assess publication bias. ETHICS AND DISSEMINATION Since primary data are not collected in this study, ethical approval is not required. This review is expected to provide relevant data on the associations between various air pollutants' exposure and renal outcomes. The final report will be published in an international peer-reviewed journal. PROSPERO REGISTRATION NUMBER CRD42020187956.
Collapse
Affiliation(s)
- Aghilès Hamroun
- Nephrology, Regional and University Hospital Centre Lille, Lille, France
- Clinical Epidemiology Team, INSERM U1018, Villejuif, France
| | - Aurore Camier
- Research Team on Early Life Origins of Health (EAROH), UMR1153 Centre of Research in Epidemiology and Statistics (CRESS), Paris, France
| | - Jean Joel Bigna
- Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé, Cameroon
| | - François Glowacki
- Nephrology, Regional and University Hospital Centre Lille, Lille, France
| |
Collapse
|
19
|
Paccou J, Pflimlin A, Glowacki F, Cortet B. A Challenging Case of Tumor-Induced Osteomalacia. Am J Med 2021; 134:e60-e61. [PMID: 32712146 DOI: 10.1016/j.amjmed.2020.06.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 06/04/2020] [Accepted: 06/07/2020] [Indexed: 10/23/2022]
Affiliation(s)
- Julien Paccou
- MABLab ULR 4490, Department of Rheumatology, Universitaire de Lille, Centre Hospitalier Universitaire de Lille, Lille, France.
| | - Arnaud Pflimlin
- Department of Rheumatology, Universitaire de Lille, Centre Hospitalier Universitaire de Lille, Lille, France
| | - François Glowacki
- Department of Nephrology, Universitaire de Lille, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Bernard Cortet
- MABLab ULR 4490, Department of Rheumatology, Universitaire de Lille, Centre Hospitalier Universitaire de Lille, Lille, France
| |
Collapse
|
20
|
Petit V, Bonnafous P, Fages V, Gautheret-Dejean A, Engelmann I, Baras A, Hober D, Gérard R, Gibier JB, Leteurtre E, Glowacki F, Moulonguet F, Decaestecker A, Provôt F, Chamley P, Faure E, Prusty BK, Maanaoui M, Hazzan M. Donor-to-recipient transmission and reactivation in a kidney transplant recipient of an inherited chromosomally integrated HHV-6A: Evidence and outcomes. Am J Transplant 2020; 20:3667-3672. [PMID: 32428994 DOI: 10.1111/ajt.16067] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 05/04/2020] [Accepted: 05/07/2020] [Indexed: 01/25/2023]
Abstract
Human herpesvirus (HHV)-6A can be inherited and chromosomally integrated (iciHHV-6A), and donor-to-recipient transmission has been reported in solid organ transplant. However, when HHV-6A reactivation happens after transplant, the source of HHV-6A is often not evident and its pathogenicity remains unclear. Here, we present an exhaustive case of donor-to-recipient transmission and reactivation of iciHHV-6A through kidney transplant. The absence of HHV-6A genome from the nails of the recipient excluded a recipient-related iciHHV-6A. Viral loads > 7 log10 copies/106 cells in donor blood samples and similarities of U38, U39, U69, and U100 viral genes between donor, recipient, and previously published iciHHV-6A strains are proof of donor-related transmission. Detection of noncoding HHV-6 snc-RNA14 using fluorescence in situ hybridization analysis and immunofluorescence staining of HHV-6A gp82/gp105 late proteins on kidney biopsies showed evidence of reactivation in the transplanted kidney. Because HHV-6A reactivation can be life threatening in immunocompromised patients, we provide several tools to help during the complete screening and diagnosis.
Collapse
Affiliation(s)
- Vivien Petit
- Service de Néphrologie, CHU Lille, Lille, France
| | - Pascale Bonnafous
- Sorbonne Department, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), THERAVIR Team, Paris, France
| | - Victor Fages
- Service de Néphrologie, CHU Lille, Lille, France
| | - Agnès Gautheret-Dejean
- Service de Virologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France.,Faculté de Pharmacie de Paris, Laboratoire de Microbiologie, Université de Paris, UMR-S 1139 (3PHM), Paris, France
| | - Ilka Engelmann
- Laboratoire de Virologie ULR3610, University of Lille, CHU Lille, Lille, France
| | - Agathe Baras
- Laboratoire de Virologie ULR3610, University of Lille, CHU Lille, Lille, France
| | - Didier Hober
- Laboratoire de Virologie ULR3610, University of Lille, CHU Lille, Lille, France
| | - Romain Gérard
- Gastroenterology Department, University of Lille, CHU Lille, Lille, France
| | - Jean-Baptiste Gibier
- Centre de Biologie Pathologie, Institute of Pathology, CHU Lille, Lille, France.,University of Lille, INSERM UMR1172, Lille, France
| | - Emmanuelle Leteurtre
- Centre de Biologie Pathologie, Institute of Pathology, CHU Lille, Lille, France.,University of Lille, INSERM UMR1172, Lille, France
| | - François Glowacki
- Service de Néphrologie, CHU Lille, Lille, France.,UnivErsity of Lille, Lille, France
| | | | | | | | - Paul Chamley
- Service de Néphrologie, CHU Lille, Lille, France
| | - Emmanuel Faure
- Service de Maladies Infectieuses, CHU Lille, Lille, France.,U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, CHU Lille, UnivErsity of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France
| | - Bhupesh K Prusty
- Institut für Virologie und Immunobiologie, Julius-Maximilians-Universität Würzburg, Würzburg, Germany
| | - Mehdi Maanaoui
- Service de Néphrologie, CHU Lille, Lille, France.,University of Lille, INSERM U1190, Translational Research for Diabetes, Lille, France
| | - Marc Hazzan
- Service de Néphrologie, CHU Lille, Lille, France
| |
Collapse
|
21
|
Gnemmi V, Gibier JB, Humez S, Copin MC, Glowacki F. [Renal granulomatous nephritis: Histopathological point of view]. Ann Pathol 2020; 41:166-175. [PMID: 33277052 DOI: 10.1016/j.annpat.2020.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Revised: 07/22/2020] [Accepted: 11/03/2020] [Indexed: 11/29/2022]
Abstract
Granulomatous interstitial nephritis (NIG) is a rare form of interstitial nephritis that can be related to acute or chronic clinical presentation. NIG is characterized by granulomas located to the renal interstitium and composed of either epithelioid histiocytes with giant cells and/or of foreign body reaction. The symptoms are unspecific and associate varying degrees of renal failure with abnormal urinanalysis. Extra-renal signs may point to systemic disease. Pathological examination from kidney percutaneous biopsy or surgical resection is required to assert NIG diagnosis and to guide the etiological research. The main causes of NIG are sarcoidosis, drug reactions, mycobacterial infections and crystalline nephropathies. Sarcoidosis is characterized by non-necrotic and well-formed giant cell epithelioid interstitial granulomas. Drug reactions have less well-defined granulomas with inconstant eosinophils. The presence of caseous necrosis within giant cell and epithelioid granulomas leads to infectious NIG diagnosis (tuberculosis and fungal infection). Identification of crystals within foreign body reaction can be improved by polarized light study. Xanthogranulomatous pyelonephritis and malakoplakia are rarer causes of NIG characterized by patches of histiocytes associated with inconstant giant cells. Differential diagnoses of NIG are represented by granulomatous reactions centered on glomeruli and vessels (vasculitis and emboli of cholesterol crystals). Less than 10% of NIG are idiopathic. The prognosis and the treatment vary according to the cause. The factors of poor renal prognosis are chronic irreversible tubulo-interstitial injury (tubular atrophy and interstitial fibrosis).
Collapse
Affiliation(s)
- Viviane Gnemmi
- UMR9020 - UMR-S 1277, Inserm, CNRS, pathology department, cancer heterogeneity, plasticity and resistance to therapies, Canther, CHU de Lille, université Lille, 59000 Lille, France.
| | - Jean-Baptiste Gibier
- UMR9020 - UMR-S 1277, Inserm, CNRS, pathology department, cancer heterogeneity, plasticity and resistance to therapies, Canther, CHU de Lille, université Lille, 59000 Lille, France
| | - Sarah Humez
- UMR9020 - UMR-S 1277, Inserm, CNRS, pathology department, cancer heterogeneity, plasticity and resistance to therapies, Canther, CHU de Lille, Institut Pasteur de Lille, université Lille, 59000 Lille, France
| | - Marie-Christine Copin
- UMR9020 - UMR-S 1277, Inserm, CNRS, pathology department, cancer heterogeneity, plasticity and resistance to therapies, Canther, CHU de Lille, Institut Pasteur de Lille, université Lille, 59000 Lille, France
| | - François Glowacki
- UMR9020 - UMR-S 1277, Inserm, CNRS, nephrology department, cancer heterogeneity, plasticity and resistance to therapies, Canther, CHU de Lille, université Lille, 59000 Lille, France
| |
Collapse
|
22
|
Hamroun A, Camier A, Bigna J, Glowacki F. Impact de la pollution de l’air sur la santé rénale : revue systématique et méta-analyse. Nephrol Ther 2020. [DOI: 10.1016/j.nephro.2020.07.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Ferreira JP, Couchoud C, Gregson J, Tiple A, Glowacki F, London G, Agarwal R, Rossignol P. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study. Nephrol Dial Transplant 2020; 34:1216-1222. [PMID: 30590716 DOI: 10.1093/ndt/gfy378] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), β-blockers or both in all-cause mortality rates in incident ESRD patients without known CV disease starting renal replacement therapy (RRT) between 2009 and 2015 in the nationwide Réseau Epidémiologie et Information en Néphrologie registry. METHODS Patients with known CV disease and those who started emergency RRT, stopped RRT or died within 6 months were excluded. Propensity score matching models were used. The main outcome was all-cause mortality. RESULTS A total of 13 741 patients were included in this analysis. The median follow-up time was 24 months. When compared with matched controls without antihypertensive treatment, treatment with ACEi/ARBs, β-blockers and ACEi/ARBs + β-blockers was associated with an event-rate reduction per 100 person-years: ACEi/ARBs 7.6 [95% confidence interval (CI) 7.1-8.2] versus matched controls 9.5 (8.8-10.1) [HR 0.76 (95% CI 0.69-0.84)], β-blocker 7.1 (6.6-7.7) versus matched controls 9.5 (8.5-10.2) [HR 0.72 (0.65-0.80)] and ACEi/ARBs + β-blockers 5.8 (5.4-6.4) versus matched controls 7.8 (7.2-8.4) [HR 0.68 (0.61-0.77)]. CONCLUSIONS Neurohormonal blocking therapies were associated with death rate reduction in incident ESRD without CV disease. Whether these relationships are causal will require randomized controlled trials.
Collapse
Affiliation(s)
- João Pedro Ferreira
- Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique, UMR, CHRU de Nancy, Nancy, France.,F-CRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, France, Nancy.,Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal
| | - Cécile Couchoud
- Agence de la biomédecine, Avenue du Stade-de-France, Saint-Denis-La-Plaine Cedex, France
| | - John Gregson
- London School of Hygiene and Tropical Medicine, London, UK
| | - Aurélien Tiple
- Service de Néphrologie, CHRU de Clermont-Ferrand, Clermont-Ferrand, France
| | - François Glowacki
- EA 4483-IMPECS-IMPact of Environmental Chemicals on Human Health, Faculté de Médecine/Pôle Recherche, Univ. Lille, place de Verdun, Lille Cedex, France
| | - Gerard London
- F-CRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, France, Nancy.,Department of Nephrology, Hospital Manhes, Fleury-Mérogis, France and
| | - Rajiv Agarwal
- Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA
| | - Patrick Rossignol
- Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique, UMR, CHRU de Nancy, Nancy, France.,F-CRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, France, Nancy
| |
Collapse
|
24
|
Savary G, Dewaeles E, Diazzi S, Buscot M, Nottet N, Fassy J, Courcot E, Henaoui IS, Lemaire J, Martis N, Van der Hauwaert C, Pons N, Magnone V, Leroy S, Hofman V, Plantier L, Lebrigand K, Paquet A, Lino Cardenas CL, Vassaux G, Hofman P, Günther A, Crestani B, Wallaert B, Rezzonico R, Brousseau T, Glowacki F, Bellusci S, Perrais M, Broly F, Barbry P, Marquette CH, Cauffiez C, Mari B, Pottier N. The Long Noncoding RNA DNM3OS Is a Reservoir of FibromiRs with Major Functions in Lung Fibroblast Response to TGF-β and Pulmonary Fibrosis. Am J Respir Crit Care Med 2020; 200:184-198. [PMID: 30964696 DOI: 10.1164/rccm.201807-1237oc] [Citation(s) in RCA: 71] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Rationale: Given the paucity of effective treatments for idiopathic pulmonary fibrosis (IPF), new insights into the deleterious mechanisms controlling lung fibroblast activation, the key cell type driving the fibrogenic process, are essential to develop new therapeutic strategies. TGF-β (transforming growth factor-β) is the main profibrotic factor, but its inhibition is associated with severe side effects because of its pleiotropic role. Objectives: To determine if downstream noncoding effectors of TGF-β in fibroblasts may represent new effective therapeutic targets whose modulation may be well tolerated. Methods: We investigated the whole noncoding fraction of TGF-β-stimulated lung fibroblast transcriptome to identify new genomic determinants of lung fibroblast differentiation into myofibroblasts. Differential expression of the long noncoding RNA (lncRNA) DNM3OS (dynamin 3 opposite strand) and its associated microRNAs (miRNAs) was validated in a murine model of pulmonary fibrosis and in IPF tissue samples. Distinct and complementary antisense oligonucleotide-based strategies aiming at interfering with DNM3OS were used to elucidate the role of DNM3OS and its associated miRNAs in IPF pathogenesis. Measurements and Main Results: We identified DNM3OS as a fibroblast-specific critical downstream effector of TGF-β-induced lung myofibroblast activation. Mechanistically, DNM3OS regulates this process in trans by giving rise to three distinct profibrotic mature miRNAs (i.e., miR-199a-5p/3p and miR-214-3p), which influence SMAD and non-SMAD components of TGF-β signaling in a multifaceted way. In vivo, we showed that interfering with DNM3OS function not only prevents lung fibrosis but also improves established pulmonary fibrosis. Conclusions: Pharmacological approaches aiming at interfering with the lncRNA DNM3OS may represent new effective therapeutic strategies in IPF.
Collapse
Affiliation(s)
- Grégoire Savary
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France.,2 EA 4483-IMPECS and
| | | | - Serena Diazzi
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | - Matthieu Buscot
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France.,3 Département de Pneumologie, CHU-Nice
| | - Nicolas Nottet
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | - Julien Fassy
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | | | - Imène-Sarah Henaoui
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | | | - Nihal Martis
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France.,3 Département de Pneumologie, CHU-Nice
| | | | - Nicolas Pons
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | - Virginie Magnone
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | - Sylvie Leroy
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France.,3 Département de Pneumologie, CHU-Nice
| | - Véronique Hofman
- 4 Laboratory of Clinical and Experimental Pathology and Hospital-Integrated Biobank (BB-0033-00025), CHU Nice, and.,5 CNRS, INSERM, Institute for Research on Cancer and Aging, FHU-OncoAge, Université Côte d'Azur, Nice, France
| | - Laurent Plantier
- 6 Centre d'Étude des Pathologies Respiratoires-CEPR, INSERM, UMR1100, Labex Mabimprove, Université François Rabelais, Tours, France
| | - Kevin Lebrigand
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | - Agnès Paquet
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | | | - Georges Vassaux
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | - Paul Hofman
- 4 Laboratory of Clinical and Experimental Pathology and Hospital-Integrated Biobank (BB-0033-00025), CHU Nice, and.,5 CNRS, INSERM, Institute for Research on Cancer and Aging, FHU-OncoAge, Université Côte d'Azur, Nice, France
| | - Andreas Günther
- 7 Center for Interstitial and Rare Diseases and Cardiopulmonary Institute and.,8 European IPF Registry and Biobank and
| | - Bruno Crestani
- 8 European IPF Registry and Biobank and.,9 Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, INSERM U1152, Université Paris Diderot, LABEX Inflamex, DHU FIRE, Paris, France; and
| | | | - Roger Rezzonico
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | - Thierry Brousseau
- 11 Service de Biochimie Automatisée, Protéines et Biologie Prédictive
| | | | - Saverio Bellusci
- 13 Excellence Cluster Cardio-Pulmonary System, German Center for Lung Research, Justus-Liebig-University Gießen, Giessen, Germany
| | | | - Franck Broly
- 2 EA 4483-IMPECS and.,15 Service de Toxicologie et Génopathies, CHU Lille, Lille, France
| | - Pascal Barbry
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | | | | | - Bernard Mari
- 1 CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge, Université Côte d'Azur, Valbonne, France
| | - Nicolas Pottier
- 2 EA 4483-IMPECS and.,15 Service de Toxicologie et Génopathies, CHU Lille, Lille, France
| |
Collapse
|
25
|
Hamroun A, Lenain R, Bigna JJ, Speyer E, Bui L, Chamley P, Pottier N, Cauffiez C, Dewaeles E, Dhalluin X, Scherpereel A, Hazzan M, Maanaoui M, Glowacki F. Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis. Drugs 2020; 79:1567-1582. [PMID: 31429065 DOI: 10.1007/s40265-019-01182-1] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
PURPOSE Cisplatin-induced acute kidney injury (CIA) is a serious adverse event that affects 20-40% of exposed patients, despite any implemented precaution to avoid it. The aim of this work was therefore to identify a relevant nephroprotective method for CIA. METHODS We searched Pubmed, Embase, and Web of Science from 1 January 1978 to 1 June 2018, without language restriction. All studies (observational and interventional) assessing a CIA prevention method for adults receiving at least one course of cisplatin were eligible. The primary outcome was acute nephrotoxicity, as defined by the AKI-KDIGO classification (2012). The odds ratio and corresponding 95% confidence interval were used to assess the associations. We used narrative synthesis in case of heterogeneity regarding intervention, population, or outcome. When possible, a random-effects model was used to pool studies. The heterogeneity between studies was quantified (I2), and multiple meta-regressions were carried out to identify potential confounders. RESULTS Within 4520 eligible studies, 51 articles fulfilling the selection criteria were included in the review, assessing 21 different prevention methods. A meta-analysis could only be performed on the 15 observational studies concerning magnesium supplementation (1841 patients), and showed a significant nephroprotective effect for all combined grades of CIA (OR 0.24, [0.19-0.32], I2 = 0.0%). This significant nephroprotective effect was also observed for grades 2 and 3 CIA (OR 0.22, [0.14-0.33], I2 = 0.0% and OR 0.25, [0.08-0.76], I2 = 0.0%, respectively). CONCLUSION While no method of prevention had so far demonstrated its indisputable efficacy, our results highlight the potential protective effect of magnesium supplementation on cisplatin-induced acute nephrotoxicity. TRIAL REGISTRATION This study is registered in PROSPERO, CRD42018090612.
Collapse
Affiliation(s)
- Aghilès Hamroun
- Nephrology Department, CHRU Lille, University of Lille, 59000, Lille, France.
| | - Rémi Lenain
- Nephrology Department, CHRU Lille, University of Lille, 59000, Lille, France
| | - Jean Joel Bigna
- Faculty of Medicine, University of Paris Saclay, Paris, France
| | - Elodie Speyer
- Centre for Research in Epidemiology and Population Health (CESP), Paris Saclay University, Paris Sud University, Versailles Saint Quentin University, INSERM UMRS 1018, 94807, Villejuif, France
| | - Linh Bui
- Nephrology Department, CH Beuvry, Béthune, France
| | - Paul Chamley
- Nephrology Department, CHRU Lille, University of Lille, 59000, Lille, France
| | - Nicolas Pottier
- Department of Toxicology and Genetic Pathologies, CHRU Lille, 59000, Lille, France
| | - Christelle Cauffiez
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Medicine Faculty, Research Department, University of Lille, 59045, Lille, France
| | - Edmone Dewaeles
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Medicine Faculty, Research Department, University of Lille, 59045, Lille, France
| | - Xavier Dhalluin
- Pulmonary and Thoracic Oncology Department, University of Lille, INSERM U1189 OncoThAI, 59000, Lille, France
| | - Arnaud Scherpereel
- Pulmonary and Thoracic Oncology Department, University of Lille, INSERM U1189 OncoThAI, 59000, Lille, France
| | - Marc Hazzan
- Nephrology Department, CHRU Lille, University of Lille, 59000, Lille, France
- INSERM, UMR995, 59000, Lille, France
| | - Mehdi Maanaoui
- Nephrology Department, CHRU Lille, University of Lille, 59000, Lille, France
| | - François Glowacki
- Nephrology Department, CHRU Lille, University of Lille, 59000, Lille, France
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Medicine Faculty, Research Department, University of Lille, 59045, Lille, France
| |
Collapse
|
26
|
Delsart P, Vambergue A, Ninni S, Machuron F, Lelievre B, Ledieu G, Fontaine P, Merlen E, Frimat M, Glowacki F, Montaigne D, Mounier-Vehier C. Prognostic significance of the renal resistive index in the primary prevention of type II diabetes. J Clin Hypertens (Greenwich) 2020; 22:223-230. [PMID: 32003935 DOI: 10.1111/jch.13819] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 11/21/2019] [Accepted: 12/02/2019] [Indexed: 12/20/2022]
Abstract
The renal resistive index has been demonstrated to predict the progression of renal disease and recurrence of major cardiac events in high-risk cardiovascular patients, in addition to other comorbidities. We aimed to assess the prognostic significance of the renal resistive index in type 2 diabetic patients for primary prevention. From 2008 to 2011, patients with type 2 diabetes underwent cardiovascular evaluation, including renal resistive index assessment by renal Doppler ultrasound. The incidence of all-cause death, cardiovascular events, dialysis requirement or a twofold increase in creatinine was recorded. Survival curves were estimated by the Kaplan-Meier method. Two hundred sixty-six patients were included; 50% of the patients were men, an HbA1C level of 8.1 ± 1.7% (65 ± 13.6 mmol/mol) and a serum creatinine level of 8 [7-9] mg/L. The mean 24-hour systolic blood pressure, 24-hour diastolic blood pressure, and 24-hour pulse pressure were 133.4 ± 16.7, 76.5 ± 9.4, and 56.9 ± 12.4 mm Hg, respectively. The median renal resistive index was 0.7 [0.6-0.7] with a threshold of 0.7 predictive of monitored events. After adjustment of the 24-hour pulse pressure, age and 24-hour heart rate, a renal resistive index ≥0.70 remained associated with all-cause death (hazard ratio: 3.23 (1.16-8.98); P = .025) and the composite endpoint of major clinical events (hazard ratio: 2.37 (1.34-4.18); P = .003). An elevated renal resistive index with a threshold of 0.7 is an independent predictor of a first cardiovascular or renal event in type 2 diabetic patients. This simple index should be implemented in the multiparametric staging of diabetes.
Collapse
Affiliation(s)
| | - Anne Vambergue
- CHU Lille, University of Lille, Lille, France.,Endocrinology, Diabetology and Metabolism, CHU Lille, Lille, France
| | - Sandro Ninni
- Institut Cœur Poumon, CHU Lille, Lille, France.,CHU Lille, University of Lille, Lille, France
| | - François Machuron
- CHU Lille, EA 2694 - Santé Publique: Épidémiologie et Qualité des Soins, Department of Biostatistics, Univ. Lille, Lille, France
| | | | | | - Pierre Fontaine
- CHU Lille, University of Lille, Lille, France.,Endocrinology, Diabetology and Metabolism, CHU Lille, Lille, France
| | - Emilie Merlen
- CHU Lille, University of Lille, Lille, France.,Endocrinology, Diabetology and Metabolism, CHU Lille, Lille, France
| | - Marie Frimat
- CHU Lille, University of Lille, Lille, France.,CHU Lille, EA4483 IMPECS, Department of Nephrology, Univ. Lille, Lille, France
| | - François Glowacki
- CHU Lille, University of Lille, Lille, France.,CHU Lille, EA4483 IMPECS, Department of Nephrology, Univ. Lille, Lille, France
| | - David Montaigne
- Institut Cœur Poumon, CHU Lille, Lille, France.,CHU Lille, University of Lille, Lille, France.,Institut Pasteur de Lille, EGID. Inserm U1011, Lille, France
| | - Claire Mounier-Vehier
- Institut Cœur Poumon, CHU Lille, Lille, France.,CHU Lille, University of Lille, Lille, France
| |
Collapse
|
27
|
Pekar JD, Grzych G, Durand G, Haas J, Lionet A, Brousseau T, Glowacki F, Maboudou P. Calcium state estimation by total calcium: the evidence to end the never-ending story. Clin Chem Lab Med 2020; 58:222-231. [PMID: 31473684 DOI: 10.1515/cclm-2019-0568] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Accepted: 08/07/2019] [Indexed: 01/31/2023]
Abstract
Background Total blood calcium (TCa) is routinely used to diagnose and manage mineral and bone metabolism disorders. Numerous laboratories adjust TCa by albumin, though literature suggests there are some limits to this approach. Here we report a large retrospective study on agreement rate between ionized calcium (iCa) measurement and TCa or albumin-adjusted calcium measurements. Methods We retrospectively selected 5055 samples with simultaneous measurements of iCa, TCa, albumin and pH. We subgrouped our patients according to their estimated glomerular filtration rate (eGFR), albumin levels and pH. We analyzed each patient's calcium state with iCa as reference to determine agreement rate with TCa and albumin-adjusted calcium using Payne, Clase, Jain and Ridefelt formulas. Results The Payne formula performed poorly in patients with abnormal albumin, eGFR or pH levels. In patients with low albumin levels or blood pH disorders, Payne-adjusted calcium may overestimate the calcium state in up to 80% of cases. Similarly, TCa has better agreement with iCa in the case of hypoalbuminemia, but performed similarly to the Payne formula in patients with physiological albumin levels. The global agreement rate for Clase, Jain and Ridefelt formulas suggests significant improvement compared to Payne calcium adjustment but no significant improvement compared to TCa. Conclusions Total and albumin-adjusted calcium measurement leads to a misclassification of calcium status. Moreover, accurate calcium state determination depends on blood pH levels, whose measurement requires the same pre-analytical restrictions as iCa measurement. We propose that iCa should instead become the reference method to determine the real calcium state.
Collapse
Affiliation(s)
| | - Guillaume Grzych
- Centre de Biologie Pathologie, Laboratoire d'Hormonologie, Métabolisme-Nutrition, Oncologie, rue du Pr J. Leclercq, CHU Lille, F-59000 Lille, France.,Université de Lille, INSERM UMR-1011, Lille, France
| | - Gatien Durand
- CHU Lille, UF 8832 Biochimie automatisée, Lille, France
| | - Joël Haas
- Université de Lille, INSERM UMR-1011, Lille, France
| | - Arnaud Lionet
- CHU Lille, Service de Néphrologie et Transplantation, Lille, France
| | | | | | | |
Collapse
|
28
|
Lemaire J, Van der Hauwaert C, Savary G, Dewaeles E, Perrais M, Lo Guidice JM, Pottier N, Glowacki F, Cauffiez C. Cadmium-Induced Renal Cell Toxicity Is Associated With MicroRNA Deregulation. Int J Toxicol 2020; 39:103-114. [DOI: 10.1177/1091581819899039] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Cadmium is an environmental pollutant well known for its nephrotoxic effects. Nevertheless, mechanisms underlying nephrotoxicity continue to be elucidated. MicroRNAs (miRNAs) have emerged in recent years as modulators of xenobiotic-induced toxicity. In this context, our study aimed at elucidating whether miRNAs are involved in renal proximal tubular toxicity induced by cadmium exposure. We showed that cadmium exposure, in 2 distinct renal proximal tubular cell models (renal proximal tubular epithelial cell [RPTEC]/human telomerase reverse transcriptase [hTERT] and human kidney-2), resulted in cytotoxicity associated with morphological changes, overexpression of renal injury markers, and induction of apoptosis and inflammation processes. Cadmium exposure also resulted in miRNA modulation, including the significant upregulation of 38 miRNAs in RPTEC/hTERT cells. Most of these miRNAs are known to target genes whose coding proteins are involved in oxidative stress, inflammation, and apoptosis, leading to tissue remodeling. In conclusion, this study provides a list of dysregulated miRNAs which may play a role in the pathophysiology of cadmium-induced kidney damages and highlights promising cadmium molecular biomarkers that warrants to be further evaluated.
Collapse
Affiliation(s)
- J. Lemaire
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Université de Lille, Lille Cedex, France
| | - C. Van der Hauwaert
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Université de Lille, Lille Cedex, France
- Département de la Recherche en Santé, CHU Lille, Lille, France
| | - G. Savary
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Université de Lille, Lille Cedex, France
| | - E. Dewaeles
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Université de Lille, Lille Cedex, France
| | - M. Perrais
- UMR-S 1172-JPArc-Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, Université de Lille, Lille, France
| | - J. M. Lo Guidice
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Université de Lille, Lille Cedex, France
| | - N. Pottier
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Université de Lille, Lille Cedex, France
- Service de Toxicologie et Génopathies, CHU Lille, Lille, France
| | - F. Glowacki
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Université de Lille, Lille Cedex, France
- Service de Néphrologie, CHU Lille, Lille, France
| | - C. Cauffiez
- EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Université de Lille, Lille Cedex, France
| |
Collapse
|
29
|
Robert L, Ficheur G, Gautier S, Servais A, Luyckx M, Soula J, Decaudin B, Glowacki F, Puisieux F, Chazard E, Beuscart JB. Community-Acquired Acute Kidney Injury Induced By Drugs In Older Patients: A Multifactorial Event. Clin Interv Aging 2019; 14:2105-2113. [PMID: 31824141 PMCID: PMC6901120 DOI: 10.2147/cia.s217567] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 09/25/2019] [Indexed: 12/12/2022] Open
Abstract
Purpose Community-acquired acute kidney injury (CA-AKI) is a frequent and severe adverse drug reaction (ADR) among older patients. The combination of drugs and other CA-AKI risk factors was barely evaluated. The objectives of our study were to both accurately identify CA-AKI induced by drugs in older patients, and to describe their combination with other risk factors. Patients and methods We conducted a retrospective, single-center study in a general hospital over a two-year period. An automated detection identified CA-AKI according to KDIGO criteria, amongst 4,767 eligible inpatient stays among patients aged 75 years or older. Two independent experts reviewed all CA-AKI events to adjudicate drug involvement (Naranjo scale), identify inappropriate prescriptions (STOPP criteria), evaluate avoidability (Hallas criteria) and identify combined risk factors. Results An expert review confirmed 713 CA-AKI (15.0% of inpatient stays) and determined that 419 (58.8%) CA-AKI were induced by drugs. A multifactorial cause (i.e., at least one drug with a precipitating factor) was found in 63.2% of drug-induced CA-AKI. Most of the drug-induced events were avoidable (66.8%), mainly in relation to a multifactorial cause. Conclusion Drug-induced CA-AKI were frequent, multifactorial events in hospitalized older patients and their prevention should focus on combinations with precipitating factors.
Collapse
Affiliation(s)
| | - Grégoire Ficheur
- Univ. Lille, CHU Lille, EA2694, Public Health Department, Lille, F-59000, France
| | - Sophie Gautier
- Univ. Lille, CHU Lille, UMR 1171, Department of Pharmacology, Lille, F-59000, France
| | | | - Michel Luyckx
- Univ. Lille, EA7365, F-59000 Lille, CH Denain, Department of Pharmacy, Denain, F-59220, France
| | - Julien Soula
- Univ. Lille, CHU Lille, EA2694, Lille, F-59000, France
| | - Bertrand Decaudin
- Univ. Lille, CHU Lille, EA7365, Department of Pharmacy, Lille, F-59000, France
| | - François Glowacki
- Univ. Lille, CHU Lille, EA4483 IMPECS, Department of Nephrology, Lille, F-59000, France
| | | | - Emmanuel Chazard
- Univ. Lille, CHU Lille, EA2694, Public Health Department, Lille, F-59000, France
| | | |
Collapse
|
30
|
Hamroun A, Frimat M, Beuscart JB, Buob D, Lionet A, Lebas C, Daroux M, Provôt F, Hazzan M, Boulanger É, Glowacki F. [Kidney disease care for the elderly]. Nephrol Ther 2019; 15:533-552. [PMID: 31711751 DOI: 10.1016/j.nephro.2019.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
In our aging population, kidney disease management needs to take into account the frailty of the elderly. Standardized geriatric assessments can be proposed to help clinicians apprehend this dimension in their daily practice. These tools allow to better identify frail patients and offer them more personalized and harmless treatments. This article aims to focus on the kidney diseases commonly observed in elderly patients and analyze their specific nephrogeriatric care modalities. It should be noticed that all known kidney diseases can be also observed in the elderly, most often with a quite similar clinical presentation. This review is thus focused on the diseases most frequently and most specifically observed in elderly patients (except for monoclonal gammopathy associated nephropathies, out of the scope of this work), as well as the peculiarities of old age nephrological care.
Collapse
Affiliation(s)
- Aghilès Hamroun
- Service de néphrologie, hôpital Huriez, CHRU de Lille, 59037 Lille, France
| | - Marie Frimat
- Service de néphrologie, hôpital Huriez, CHRU de Lille, 59037 Lille, France
| | | | - David Buob
- Service d'anatomopathologie, Centre de biologie-pathologie, CHRU de Lille, 59037 Lille, France
| | - Arnaud Lionet
- Service de néphrologie, hôpital Huriez, CHRU de Lille, 59037 Lille, France
| | - Céline Lebas
- Service de néphrologie, hôpital Huriez, CHRU de Lille, 59037 Lille, France
| | - Maïté Daroux
- Service de néphrologie, hôpital Duchenne, allée Jacques Monod, 62200 Boulogne-sur-Mer, France
| | - François Provôt
- Service de néphrologie, hôpital Huriez, CHRU de Lille, 59037 Lille, France
| | - Marc Hazzan
- Service de néphrologie, hôpital Huriez, CHRU de Lille, 59037 Lille, France
| | - Éric Boulanger
- Service de gériatrie, CHRU de Lille, 59037 Lille, France
| | - François Glowacki
- Service de néphrologie, hôpital Huriez, CHRU de Lille, 59037 Lille, France.
| |
Collapse
|
31
|
Artru F, Louvet A, Glowacki F, Bellati S, Frimat M, Gomis S, Castel H, Barthelon J, Lassailly G, Dharancy S, Noel C, Hazzan M, Mathurin P. The prognostic impact of cirrhosis on patients receiving maintenance haemodialysis. Aliment Pharmacol Ther 2019; 50:75-83. [PMID: 31087566 DOI: 10.1111/apt.15279] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 10/01/2018] [Accepted: 04/01/2019] [Indexed: 12/13/2022]
Abstract
BACKGROUND Further study is needed on the prognostic impact of cirrhosis on haemodialysis patients. AIM To evaluate cirrhosis' impact according to severity on survival and to provide therapeutic guidelines for haemodialysis cirrhotic patients. METHODS Patients with end-stage renal failure treated with haemodialysis were included retrospectively from 01/01/2000 to 31/12/2004 and prospectively from 01/01/2005 to 31/12/2014 in our French Region. Clinical data, presence of cirrhosis and its severity were recorded at the beginning of haemodialysis. The primary endpoint was 2-year survival. RESULTS Seven thousand three hundred and fifty-four patients (96%) without cirrhosis and 304 patients (4%) with cirrhosis were included. Two-year survival in noncirrhotic patients was higher than in cirrhotic patients (71.7% vs 54.4%, P < 0.0001). Patients with decompensated cirrhosis had a worse 2-year outcome (44.1%) as compared to compensated cirrhotic (62.8%, P = 0.002) and noncirrhotic patients (71.7%, P < 0.0001). Compensated and decompensated cirrhosis were independent predictive factors of 2-year mortality. In sensitivity analysis restricted to cirrhotic patients, 2-year survival of Child-Pugh A patients was higher than in Child-Pugh B and C patients (65.5% vs 27.7% vs 0%, P < 0.0001). Development of predictive models based either on severity scores (MELD and Child-Pugh) and extrahepatic comorbidities allowed correct classification of around 70% of patients in terms of mortality and may help to better stratify mortality risk in this population. CONCLUSIONS Cirrhosis is independently associated with mortality in haemodialysis patients. Patients with severe cirrhosis have a poor 2-year outcome. Severity of cirrhosis and presence of extrahepatic comorbidities should be considered when deciding to initiate renal replacement therapy.
Collapse
Affiliation(s)
- Florent Artru
- Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
| | - Alexandre Louvet
- Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
| | - François Glowacki
- Hôpital Claude Huriez, Service de Néphrologie et de dialyse CHRU Lille, Lille, France
| | - Sara Bellati
- Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
| | - Marie Frimat
- Hôpital Claude Huriez, Service de Néphrologie et de dialyse CHRU Lille, Lille, France
| | - Sebastien Gomis
- Hôpital Claude Huriez, Service de Néphrologie et de dialyse CHRU Lille, Lille, France
| | - Hélène Castel
- Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
| | - Justine Barthelon
- Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
| | - Guillaume Lassailly
- Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
| | - Sebastien Dharancy
- Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
| | - Christian Noel
- Hôpital Claude Huriez, Service de Néphrologie et de dialyse CHRU Lille, Lille, France
| | - Marc Hazzan
- Hôpital Claude Huriez, Service de Néphrologie et de dialyse CHRU Lille, Lille, France
| | - Philippe Mathurin
- Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
| |
Collapse
|
32
|
Durand G, Pekar J, Maboudou P, Lionet A, Glowacki F, Grzych G. Misclassification of calcium state according to clinical variations. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.1027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
33
|
Teissier T, Quersin V, Gnemmi V, Daroux M, Howsam M, Delguste F, Lemoine C, Fradin C, Schmidt AM, Cauffiez C, Brousseau T, Glowacki F, Tessier FJ, Boulanger E, Frimat M. Knockout of receptor for advanced glycation end-products attenuates age-related renal lesions. Aging Cell 2019; 18:e12850. [PMID: 30794349 PMCID: PMC6413655 DOI: 10.1111/acel.12850] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 09/04/2018] [Accepted: 09/09/2018] [Indexed: 01/10/2023] Open
Abstract
Pro‐aging effects of endogenous advanced glycation end‐products (AGEs) have been reported, and there is increasing interest in the pro‐inflammatory and ‐fibrotic effects of their binding to RAGE (the main AGE receptor). The role of dietary AGEs in aging remains ill‐defined, but the predominantly renal accumulation of dietary carboxymethyllysine (CML) suggests the kidneys may be particularly affected. We studied the impact of RAGE invalidation and a CML‐enriched diet on renal aging. Two‐month‐old male, wild‐type (WT) and RAGE−/− C57Bl/6 mice were fed a control or a CML‐enriched diet (200 μg CML/gfood) for 18 months. Compared to controls, we observed higher CML levels in the kidneys of both CML WT and CML RAGE−/− mice, with a predominantly tubular localization. The CML‐rich diet had no significant impact on the studied renal parameters, whereby only a trend to worsening glomerular sclerosis was detected. Irrespective of diet, RAGE−/− mice were significantly protected against nephrosclerosis lesions (hyalinosis, tubular atrophy, fibrosis and glomerular sclerosis) and renal senile apolipoprotein A‐II (ApoA‐II) amyloidosis (p < 0.001). A positive linear correlation between sclerosis score and ApoA‐II amyloidosis score (r = 0.92) was observed. Compared with old WT mice, old RAGE−/− mice exhibited lower expression of inflammation markers and activation of AKT, and greater expression of Sod2 and SIRT1. Overall, nephrosclerosis lesions and senile amyloidosis were significantly reduced in RAGE−/− mice, indicating a protective effect of RAGE deletion with respect to renal aging. This could be due to reduced inflammation and oxidative stress in RAGE−/− mice, suggesting RAGE is an important receptor in so‐called inflamm‐aging.
Collapse
Affiliation(s)
- Thibault Teissier
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
| | - Valentine Quersin
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
- Department of Nephrology; CHU Lille; Lille France
| | - Viviane Gnemmi
- Department of Pathology; U1172 - Jean-Pierre Aubert Research Center, INSERM, CHU Lille, University of Lille; Lille France
| | - Maité Daroux
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
| | - Mike Howsam
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
| | - Florian Delguste
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
| | - Cécile Lemoine
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
| | - Chantal Fradin
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
| | - Ann-Marie Schmidt
- Department of Medicine, Diabetes Research Center; NYU Langone Medical Center; New York New York
| | - Christelle Cauffiez
- EA4483 IMPECS-IMPact of Environmental ChemicalS on Human Health; CHU Lille, University of Lille; Lille France
| | - Thierry Brousseau
- UF8832 - Biochimie Automatisée; Pôle de Biologie Pathologie Génétique; CHU Lille; Lille France
| | - François Glowacki
- Department of Nephrology; CHU Lille; Lille France
- EA4483 IMPECS-IMPact of Environmental ChemicalS on Human Health; CHU Lille, University of Lille; Lille France
| | - Frédéric J. Tessier
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
| | - Eric Boulanger
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
- Department of Geriatrics; CHU Lille; Lille France
| | - Marie Frimat
- U995 - Lille Inflammation Research International Center; INSERM, CHU Lille, University of Lille; Lille France
- Department of Nephrology; CHU Lille; Lille France
| |
Collapse
|
34
|
Van Der Hauwaert C, Hennino M, Vandenbussche C, Dewaeles E, Gnemmi V, Savary G, Pottier N, Glowacki F, Cauffiez C. Implication de miR-21 dans les agressions rénales. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
35
|
Maanaoui M, Lenain R, Hamroun A, Van Der Hauwaert C, Hennart B, Pottier N, Broly F, Noël C, Cauffiez C, Glowacki F. Impact du polymorphisme génétique de la caveolin-1 du donneur en transplantation rénale. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
36
|
Maanaoui M, Provot F, Lionet A, Frimat M, Lebas C, Glowacki F, Noël C, Hazzan M. Pronostic de 116 greffes rénales issues de donneurs cadavériques de plus de 70 ans : une étude rétrospective et monocentrique. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Occelli F, Genin M, Lanier C, Glowacki F. Disparités infrarégionales d’incidence de l’insuffisance rénale chronique terminale (IRCT)–influence de la défaveur socio–économique et de l’environnement. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Simphal P, Lionet A, Gibier J, Gnemmi V, Gomis S, Provôt F, Glowacki F, Lebas C, Noël C, Hazzan M. Y-a-t-il un intérêt à réaliser une ponction biopsie rénale protocolaire à 3 mois après transplantation rénale ? Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
39
|
Rabant M, Boullenger F, Gnemmi V, Pellé G, Glowacki F, Hertig A, Brocheriou I, Suberbielle C, Taupin JL, Anglicheau D, Legendre C, Duong Van Huyen JP, Buob D. Isolated v-lesion in kidney transplant recipients: Characteristics, association with DSA, and histological follow-up. Am J Transplant 2018; 18:972-981. [PMID: 29206350 DOI: 10.1111/ajt.14617] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 11/24/2017] [Accepted: 11/25/2017] [Indexed: 01/25/2023]
Abstract
Isolated v-lesion (IvL) represents a rare and challenging situation in renal allograft biopsies because it is unknown whether IvL truly represents rejection, antibody- or T cell-mediated, or not. This multicentric retrospective study describes the clinicopathological features of IvL with an emphasis on the donor-specific antibody (DSA) status, histological follow-up, and graft survival. Inclusion criteria were the presence of v-lesion with minimal interstitial (i ≤ 1) and microvascular inflammation (g + ptc≤1). C4d-positive biopsies were excluded. We retrospectively found 33 IvL biopsies in 33 patients, mainly performed in the early posttransplantation period (median time 27 days) and clinically indicated in 66.7%. A minority of recipients (5/33, 15.2%) had DSA at the time of biopsy. IvL was treated by anti-rejection therapy in 21 cases (63.6%), whereas 12 (36.4%) were untreated. Seventy percent of untreated patients and 66% of treated patients showed favorable histological evolution on subsequent biopsy. Kidney graft survival in IvL was significantly higher than in a matched cohort of antibody-mediated rejection with arteritis. In conclusion, IvL is not primarily antibody-mediated and may show a favorable evolution. The heterogeneity of IvL pathophysiology on early biopsies should prompt DSA testing as well as close clinical and histological follow-up in all patients with IvL.
Collapse
Affiliation(s)
- Marion Rabant
- Pathology Department, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris,, France.,Paris Descartes, Sorbonne Paris Cité University, Paris, France
| | - Fanny Boullenger
- Nephrology department, Centre hospitalier intercommunal André Grégoire, Montreuil, France
| | - Viviane Gnemmi
- Pathology department, CHRU Lille, Lille 2 University, Lille, France
| | - Gaëlle Pellé
- Kidney transplant department, Foch Hospital, Suresnes, France
| | - François Glowacki
- Kidney transplant department, CHRU Lille, Lille 2 University, Lille, France
| | - Alexandre Hertig
- Kidney transplant department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Isabelle Brocheriou
- Pathology department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Sorbonne Universités, UPMC Paris 06, Paris, France.,Inserm, UMR S 1155, Paris, France
| | - Caroline Suberbielle
- Histocompatibility department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Luc Taupin
- Histocompatibility department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Dany Anglicheau
- Paris Descartes, Sorbonne Paris Cité University, Paris, France.,Department of Nephrology and Kidney transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Christophe Legendre
- Paris Descartes, Sorbonne Paris Cité University, Paris, France.,Department of Nephrology and Kidney transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Paul Duong Van Huyen
- Pathology Department, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris,, France.,Paris Descartes, Sorbonne Paris Cité University, Paris, France.,Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Paris, France
| | - David Buob
- Pathology department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Sorbonne Universités, UPMC Paris 06, Paris, France.,Inserm, UMR S 1155, Paris, France
| |
Collapse
|
40
|
Gibier JB, Gnemmi V, Glowacki F, Boyle EM, Lopez B, MacNamara E, Hoffmann M, Azar R, Guincestre T, Bourdon F, Copin MC, Buob D. Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis. Mod Pathol 2018; 31:452-462. [PMID: 29052601 DOI: 10.1038/modpathol.2017.124] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2017] [Revised: 08/02/2017] [Accepted: 08/03/2017] [Indexed: 11/09/2022]
Abstract
Light chain cast nephropathy is the most common form of kidney disease in patients with multiple myeloma. Light chain casts may occasionally show amyloid staining properties, that is, green birefringence after Congo red staining. The frequency and clinical significance of this intratubular amyloid are poorly understood. Here, we retrospectively assessed the clinicopathological features of 60 patients with histologically proven light chain cast nephropathy with a specific emphasis on intratubular amyloid, especially, its association with extrarenal systemic light chain amyloidosis. We found intratubular amyloid in 17 cases (17/60, 28%) and it was more frequent in patients with λ light chain gammopathy (13/17 in the 'intratubular amyloid' group vs 19/43 in the 'no intratubular amyloid' group, P=0.02). Pathological examination of extrarenal specimens showed that intratubular amyloid was significantly associated with the occurrence of systemic light chain amyloidosis (5/13 in the 'intratubular amyloid' group vs 0/30 in the 'no intratubular amyloid' group, P=0.001). Our results indicate that first, intratubular amyloid is not a rare finding in kidney biopsies of patients with light chain cast nephropathy, and, second, it reflects an amyloidogenic capacity of light chains that can manifest as systemic light chain amyloidosis. Thus, intratubular amyloid should be systematically screened for in kidney biopsies from patients with light chain cast nephropathy and, if detected, should prompt a work-up for associated systemic light chain amyloidosis.
Collapse
Affiliation(s)
- Jean-Baptiste Gibier
- University of Lille, Department of Pathology, Centre de Biologie Pathologie, CHU Lille, Lille, France
| | - Viviane Gnemmi
- University of Lille, Department of Pathology, Centre de Biologie Pathologie, CHU Lille, Lille, France
| | - François Glowacki
- University of Lille, Department of Nephrology, Hôpital Claude Huriez, CHU Lille, Lille, France
| | - Eileen M Boyle
- University of Lille, Department of Hematology, Hôpital Claude Huriez, CHU Lille, Lille, France
| | - Benjamin Lopez
- University of Lille, Department of Immunology, Centre de Biologie Pathologie, CHU Lille, Lille, France
| | - Evelyne MacNamara
- Department of Nephrology, Centre Hospitalier de Béthune-Beuvry, Béthune, France
| | - Maxime Hoffmann
- Department of Nephrology, Hôpital Privé de La Louvière, Lille, France
| | - Raymond Azar
- Department of Nephrology, Centre Hospitalier de Dunkerque, Dunkerque, France
| | - Thomas Guincestre
- Department of Nephrology, Centre Hospitalier de Roubaix, Roubaix, France
| | - Franck Bourdon
- Department of Nephrology, Clinique du Bois, Lille, France
| | - Marie-Christine Copin
- University of Lille, Department of Pathology, Centre de Biologie Pathologie, CHU Lille, Lille, France
| | - David Buob
- AP-HP, Hôpital Tenon, Department of Pathology, Paris, France
| |
Collapse
|
41
|
Châtelet V, Lobbedez T, Harambat J, Bayat-Makoei S, Glowacki F, Vigneau C. [Socioeconomic inequalities and kidney transplantation]. Nephrol Ther 2017; 14:81-84. [PMID: 29198520 DOI: 10.1016/j.nephro.2017.04.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Accepted: 04/04/2017] [Indexed: 11/27/2022]
Abstract
Studies at the population level must take into account the effect of social insecurity and socioeconomic inequalities on the patient outcomes. Socioeconomic inequalities depend on many determinants that are socially determined. In renal transplantation, these social determinants are not registered in the databases. The European Deprivation Index (EDI) is a composite index of social vulnerability with a French version. The EDI is an ecological measure of deprivation including the individual perception of basic needs for daily life that is called "subjective poverty". The Townsend index, Carstairs index and the Index of Multiple Deprivation are other ecological index available. It has been demonstrated in the United States that socioeconomic indicators of deprivation were associated with both the access to the waiting list for renal transplantation and transplantation failure. In France, socioeconomic deprivation may also affect the access to the waiting list and outcome of transplantation. This article is a review about deprivation and renal transplantation.
Collapse
Affiliation(s)
- Valérie Châtelet
- Centre universitaire des maladies rénales, CHU de Caen, avenue Côte-de-Nacre, CS 30001, 14033 Caen cedex 9, France.
| | - Thierry Lobbedez
- Centre universitaire des maladies rénales, CHU de Caen, avenue Côte-de-Nacre, CS 30001, 14033 Caen cedex 9, France
| | - Jérôme Harambat
- Service de pédiatrie, néphrologie pédiatrique, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - Sahar Bayat-Makoei
- EHESP Rennes, Sorbonne Paris cité, EA 7449 Repères, 15, avenue du Professeur-Léon-Bernard, CS 74312, 35043 Rennes, France
| | - François Glowacki
- Service de néphrologie, hôpital Huriez, CHRU de Lille, 2, avenue Oscar-Lambret, 59000 Lille, France
| | - Cécile Vigneau
- Service de néphrologie, CHU Pontchaillou, 2, rue Henri-le-Guilloux, 35000 Rennes, France
| |
Collapse
|
42
|
Bitton L, Vandenbussche C, Cordonnier C, Verine J, Bataille P, Azar R, Namara EM, Hatron P, Glowacki F, Copin M, Quéméneur T, Gnemmi V. Glomérulonéphrite associée aux anticorps anti-cytoplasme des polynucléaires neutrophiles (ANCA) : valeur pronostique de la fibrose interstitielle. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Perche J, Glowacki F, Samaille C, Deruelle P, Provot F, Hazzan M, Noël C, Frimat M. Grossesses menées sous anticalcineurines en transplantation rénale. Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Guise C, Hazzan M, Azar R, Bourdon F, Guincestre T, Lemoine C, Maisonneuve N, Noel C, Glowacki F. La précarité influence-t-elle l’accès à la greffe ? Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Gaudelot K, Gibier JB, Pottier N, Hémon B, Van Seuningen I, Glowacki F, Leroy X, Cauffiez C, Gnemmi V, Aubert S, Perrais M. Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumour Biol 2017; 39:1010428317707372. [PMID: 28714373 DOI: 10.1177/1010428317707372] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Renal cell carcinoma, the most common neoplasm of adult kidney, accounts for about 3% of adult malignancies and is usually highly resistant to conventional therapy. MicroRNAs are a class of small non-coding RNAs, which have been previously shown to promote malignant initiation and progression. In this study, we focused our attention on miR-21, a well described oncomiR commonly upregulated in cancer. Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome. In vitro, miR-21 was also overexpressed in renal carcinoma cell lines compared to HK-2 human proximal tubule epithelial cell line. Moreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy. Finally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression. In conclusion, our results showed that miR-21 is a key actor of renal cancer progression and plays an important role in the resistance to chemotherapeutic drugs. In renal cell carcinoma, targeting miR-21 is a potential new therapeutic strategy to improve chemotherapy efficacy and consequently patient outcome.
Collapse
Affiliation(s)
- Kelly Gaudelot
- 1 Université de Lille, Inserm, CHU Lille, UMR-S 1172, Team "Mucins, Epithelial Differentiation and Carcinogenesis," Jean-Pierre Aubert Research Center (JPARC), Lille, France
| | - Jean-Baptiste Gibier
- 1 Université de Lille, Inserm, CHU Lille, UMR-S 1172, Team "Mucins, Epithelial Differentiation and Carcinogenesis," Jean-Pierre Aubert Research Center (JPARC), Lille, France.,2 CHU Lille, Pathology Institute, Centre de Biologie Pathologie, Rue Oscar Lambret, Lille, France
| | - Nicolas Pottier
- 3 EA4483, Université de Lille, Faculté de Médecine, Pôle Recherche, Place de Verdun, Lille, France.,4 CHU Lille, Department of Biochemistry and Molecular Biology, Centre de Biologie Pathologie, Rue Oscar Lambret, Lille, France
| | - Brigitte Hémon
- 1 Université de Lille, Inserm, CHU Lille, UMR-S 1172, Team "Mucins, Epithelial Differentiation and Carcinogenesis," Jean-Pierre Aubert Research Center (JPARC), Lille, France
| | - Isabelle Van Seuningen
- 1 Université de Lille, Inserm, CHU Lille, UMR-S 1172, Team "Mucins, Epithelial Differentiation and Carcinogenesis," Jean-Pierre Aubert Research Center (JPARC), Lille, France
| | - François Glowacki
- 3 EA4483, Université de Lille, Faculté de Médecine, Pôle Recherche, Place de Verdun, Lille, France.,5 CHU Lille, Department of Nephrology, Hôpital Huriez, Rue Michel Polonovski, Lille, France
| | - Xavier Leroy
- 1 Université de Lille, Inserm, CHU Lille, UMR-S 1172, Team "Mucins, Epithelial Differentiation and Carcinogenesis," Jean-Pierre Aubert Research Center (JPARC), Lille, France.,2 CHU Lille, Pathology Institute, Centre de Biologie Pathologie, Rue Oscar Lambret, Lille, France
| | - Christelle Cauffiez
- 3 EA4483, Université de Lille, Faculté de Médecine, Pôle Recherche, Place de Verdun, Lille, France
| | - Viviane Gnemmi
- 1 Université de Lille, Inserm, CHU Lille, UMR-S 1172, Team "Mucins, Epithelial Differentiation and Carcinogenesis," Jean-Pierre Aubert Research Center (JPARC), Lille, France.,2 CHU Lille, Pathology Institute, Centre de Biologie Pathologie, Rue Oscar Lambret, Lille, France
| | - Sébastien Aubert
- 1 Université de Lille, Inserm, CHU Lille, UMR-S 1172, Team "Mucins, Epithelial Differentiation and Carcinogenesis," Jean-Pierre Aubert Research Center (JPARC), Lille, France.,2 CHU Lille, Pathology Institute, Centre de Biologie Pathologie, Rue Oscar Lambret, Lille, France
| | - Michaël Perrais
- 1 Université de Lille, Inserm, CHU Lille, UMR-S 1172, Team "Mucins, Epithelial Differentiation and Carcinogenesis," Jean-Pierre Aubert Research Center (JPARC), Lille, France
| |
Collapse
|
46
|
Hazzan M, Frimat M, Glowacki F, Lionet A, Provot F, Noël C. [New scores in renal transplantation: How can we use them?]. Nephrol Ther 2017; 13 Suppl 1:S131-S136. [PMID: 28577735 DOI: 10.1016/j.nephro.2017.01.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Accepted: 01/08/2017] [Indexed: 11/17/2022]
Abstract
In renal transplant medicine, several scores have been recently developed in order to help decision-making in clinical practice. The aim of this update is to focus on these new scores that allow to better estimate the quality of the renal transplant, to refine the allocation policy, to help registration of old recipients on the waiting list, or to evaluate the risk to develop end-stage renal failure after living donation.
Collapse
Affiliation(s)
- Marc Hazzan
- Service de néphrologie, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France; UMR 995, université de Lille, 59000 Lille, France.
| | - Marie Frimat
- Service de néphrologie, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France; UMR 995, université de Lille, 59000 Lille, France
| | - François Glowacki
- Service de néphrologie, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France
| | - Arnaud Lionet
- Service de néphrologie, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France
| | - François Provot
- Service de néphrologie, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France
| | - Christian Noël
- Service de néphrologie, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France; UMR 995, université de Lille, 59000 Lille, France
| |
Collapse
|
47
|
Gibier JB, Hémon B, Fanchon M, Gaudelot K, Pottier N, Ringot B, Van Seuningen I, Glowacki F, Cauffiez C, Blum D, Copin MC, Perrais M, Gnemmi V. Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase. Biochim Biophys Acta Mol Basis Dis 2017; 1863:1336-1349. [DOI: 10.1016/j.bbadis.2017.03.023] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2016] [Revised: 03/14/2017] [Accepted: 03/29/2017] [Indexed: 11/15/2022]
|
48
|
Vandenbussche C, Bitton L, Bataille P, Glowacki F, Azar R, Hatron PY, MacNamara E, Gheerbrant JD, Cardon G, Gnemmi V, Quemeneur T. MP183PRONOSTIC ROLE OF HEMATURIA AT REMISSION IN A RETROSPECTIVE COHORTE OF 86 PATIENTS WITH A FIRST FLARE OF ANCA-ASSOCIATED GLOMERULONEPHRITIS. Nephrol Dial Transplant 2017. [DOI: 10.1093/ndt/gfx165.mp183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Ghisdal L, Baron C, Lebranchu Y, Viklický O, Konarikova A, Naesens M, Kuypers D, Dinic M, Alamartine E, Touchard G, Antoine T, Essig M, Rerolle JP, Merville P, Taupin JL, Le Meur Y, Grall‐Jezequel A, Glowacki F, Noël C, Legendre C, Anglicheau D, Broeders N, Coppieters W, Docampo E, Georges M, Ajarchouh Z, Massart A, Racapé J, Abramowicz D, Abramowicz M. Genome-Wide Association Study of Acute Renal Graft Rejection. Am J Transplant 2017; 17:201-209. [PMID: 27272414 PMCID: PMC5215306 DOI: 10.1111/ajt.13912] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Revised: 04/29/2016] [Accepted: 05/23/2016] [Indexed: 01/25/2023]
Abstract
Acute renal rejection is a major risk factor for chronic allograft dysfunction and long-term graft loss. We performed a genome-wide association study to detect loci associated with biopsy-proven acute T cell-mediated rejection occurring in the first year after renal transplantation. In a discovery cohort of 4127 European renal allograft recipients transplanted in eight European centers, we used a DNA pooling approach to compare 275 cases and 503 controls. In an independent replication cohort of 2765 patients transplanted in two European countries, we identified 313 cases and 531 controls, in whom we genotyped individually the most significant single nucleotide polymorphisms (SNPs) from the discovery cohort. In the discovery cohort, we found five candidate loci tagged by a number of contiguous SNPs (more than five) that was never reached in iterative in silico permutations of our experimental data. In the replication cohort, two loci remained significantly associated with acute rejection in both univariate and multivariate analysis. One locus encompasses PTPRO, coding for a receptor-type tyrosine kinase essential for B cell receptor signaling. The other locus involves ciliary gene CCDC67, in line with the emerging concept of a shared building design between the immune synapse and the primary cilium.
Collapse
Affiliation(s)
- L. Ghisdal
- Department of Nephrology, Dialysis, and TransplantationHôpital Erasme (Université Libre de Bruxelles)BrusselsBelgium,Present address: Department of NephrologyCentre Hospitalier EpiCURABaudourBelgium
| | - C. Baron
- Department of NephrologyCentre Hospitalier Régional Universitaire de ToursToursFrance
| | - Y. Lebranchu
- Department of NephrologyCentre Hospitalier Régional Universitaire de ToursToursFrance
| | - O. Viklický
- Department of NephrologyTransplant CentreInstitute for Clinical and Experimental MedicinePragueCzech Republic
| | - A. Konarikova
- Department of NephrologyTransplant CentreInstitute for Clinical and Experimental MedicinePragueCzech Republic
| | - M. Naesens
- Department of Microbiology and ImmunologyKU LeuvenUniversity of LeuvenLeuvenBelgium,Department of NephrologyUniversity Hospitals LeuvenLeuvenBelgium
| | - D. Kuypers
- Department of Microbiology and ImmunologyKU LeuvenUniversity of LeuvenLeuvenBelgium,Department of NephrologyUniversity Hospitals LeuvenLeuvenBelgium
| | - M. Dinic
- Department of NephrologyCentre Hospitalier Universitaire de Saint‐EtienneSaint‐EtienneFrance
| | - E. Alamartine
- Department of NephrologyCentre Hospitalier Universitaire de Saint‐EtienneSaint‐EtienneFrance
| | - G. Touchard
- Department of NephrologyCentre Hospitalier Universitaire de PoitiersPoitiersFrance
| | - T. Antoine
- Department of NephrologyCentre Hospitalier Universitaire de PoitiersPoitiersFrance
| | - M. Essig
- Department of Nephrology, Dialysis, TransplantationCentre Hospitalier Universitaire de Limoges and INSERM UMR 850 (Université de Limoges)LimogesFrance
| | - J. P. Rerolle
- Department of Nephrology, Dialysis, TransplantationCentre Hospitalier Universitaire de Limoges and INSERM UMR 850 (Université de Limoges)LimogesFrance
| | - P. Merville
- Department of NephrologyCentre Hospitalier Universitaire de BordeauxBordeauxFrance
| | - J. L. Taupin
- Department of Immunology and HistocompatibilityHôpital Saint‐LouisParisFrance
| | - Y. Le Meur
- Department of NephrologyCentre Hospitalier Universitaire la Cavale blancheBrestFrance
| | - A. Grall‐Jezequel
- Department of NephrologyCentre Hospitalier Universitaire la Cavale blancheBrestFrance
| | - F. Glowacki
- Department of NephrologyCentre Régional Hospitalier Universitaire de LilleLilleFrance
| | - C. Noël
- Department of NephrologyCentre Régional Hospitalier Universitaire de LilleLilleFrance
| | - C. Legendre
- Department of Renal TransplantationUniversité Paris Descartes and Hôpital NeckerAssistance Publique‐Hôpitaux de ParisParisFrance
| | - D. Anglicheau
- Department of Renal TransplantationUniversité Paris Descartes and Hôpital NeckerAssistance Publique‐Hôpitaux de ParisParisFrance
| | - N. Broeders
- Department of Nephrology, Dialysis, and TransplantationHôpital Erasme (Université Libre de Bruxelles)BrusselsBelgium
| | - W. Coppieters
- Unit of Animal GenomicsGroupe Interdisciplinaire de Génoprotéomique Appliquée‐Research (GIGA‐R)University of LiègeLiègeBelgium
| | - E. Docampo
- Unit of Animal GenomicsGroupe Interdisciplinaire de Génoprotéomique Appliquée‐Research (GIGA‐R)University of LiègeLiègeBelgium
| | - M. Georges
- Unit of Animal GenomicsGroupe Interdisciplinaire de Génoprotéomique Appliquée‐Research (GIGA‐R)University of LiègeLiègeBelgium
| | - Z. Ajarchouh
- Institute of Interdisciplinary Research in Molecular and Human biology (IRIBHM)Université Libre de BruxellesBrusselsBelgium
| | - A. Massart
- Department of Nephrology, Dialysis, and TransplantationHôpital Erasme (Université Libre de Bruxelles)BrusselsBelgium,Institute of Interdisciplinary Research in Molecular and Human biology (IRIBHM)Université Libre de BruxellesBrusselsBelgium
| | - J. Racapé
- Centre of EpidemiologyBiostatistic and Clinical ResearchSchool of Public Health (Université Libre de Bruxelles)BrusselsBelgium
| | - D. Abramowicz
- Department of Nephrology, Dialysis, and TransplantationHôpital Erasme (Université Libre de Bruxelles)BrusselsBelgium,Department of NephrologyAntwerp University HospitalAntwerpenBelgium
| | - M. Abramowicz
- Institute of Interdisciplinary Research in Molecular and Human biology (IRIBHM)Université Libre de BruxellesBrusselsBelgium,Medical Genetics DepartmentHôpital Erasme (Université Libre de Bruxelles)BrusselsBelgium
| |
Collapse
|
50
|
Belaiche S, Mercier E, Cuny D, Kambia N, Wierre P, Bertoux É, Mascaut D, Azar R, Bataille P, Bourdon F, Mac Namara É, Maisonneuve N, Painchart B, Vrigneau L, Noël C, Décaudin B, Glowacki F. [Community pharmacists' interventions to prevent and screen chronic kidney disease patients]. Nephrol Ther 2016; 13:87-92. [PMID: 27810277 DOI: 10.1016/j.nephro.2016.06.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Revised: 05/20/2016] [Accepted: 06/28/2016] [Indexed: 02/08/2023]
Abstract
Chronic kidney disease (CKD) is a major concern of public health. The pharmacist is known as a health practitioner involved in prevention and therapeutic education. Our study aimed at defining the impact of community pharmacists' interventions for preventing and screening CKD. In our observational prospective study of 5 months conducted in 109 community pharmacy, we included 2 groups of patients: A (therapeutic optimization): CKD patients and B (CKD screening): population at risk. In group A, we included 354 patients, mainly women (51.2%), in stage 3 of CKD, mean age 73 years old, with hypertension alone (40.6%) or associated with diabetes (44%). About 70% of the patients had a follow up by a nephrologist and 45% of them were good adherent according to the Morisky-Green self-report. However, approximately 20% of patients did not have nephroprotective treatments in their regimen although they were on stage 3 or 4 CKD patients, and about half of them were not aware of medical situations at risk. Concerning group B, 532 patients were included. The pharmaceutical interventions screened 10% of patients with a GFR<60mL/min/1.73m2. The community pharmacists' interventions helped to optimize the therapeutic management of CKD patients and in the early screening of patients at risk. More studies are needed to extrapolate our observations to a larger population.
Collapse
Affiliation(s)
- Stéphanie Belaiche
- Institut de pharmacie, CHRU de Lille, rue Philippe-Marrache, 59000 Lille, France; EA 7365, groupe de recherche sur les formes injectables et les technologies associées (GRITA), université de Lille, 59000 Lille, France.
| | - Edwige Mercier
- Institut de pharmacie, CHRU de Lille, rue Philippe-Marrache, 59000 Lille, France
| | - Damien Cuny
- EA 4483, impact de l'environnement chimique sur la santé humaine (IMPECS), université de Lille, 59000 Lille, France
| | - Nicolas Kambia
- EA 7365, groupe de recherche sur les formes injectables et les technologies associées (GRITA), université de Lille, 59000 Lille, France
| | - Patrick Wierre
- Faculté de pharmacie, université de Lille, 59000 Lille, France
| | | | - Daniel Mascaut
- Faculté de pharmacie, université de Lille, 59000 Lille, France
| | - Raymond Azar
- Service de néphrologie, centre hospitalier de Dunkerque, 59240 Dunkerque, France
| | - Pierre Bataille
- Service de néphrologie, centre hospitalier de Boulogne-sur-Mer, 62200 Boulogne-sur-Mer, France
| | | | - Évelyne Mac Namara
- Service de néphrologie, centre hospitalier de Béthune, 62131 Béthune, France
| | - Nathalie Maisonneuve
- Service de néphrologie-dialyse, centre hospitalier de Valenciennes, 59322 Valenciennes, France
| | - Bernard Painchart
- Service de néphrologie, centre hospitalier de Cambrai, 59400 Cambrai, France
| | - Laurence Vrigneau
- Service de néphrologie-dialyse, centre hospitalier de Valenciennes, 59322 Valenciennes, France
| | - Christian Noël
- Service de néphrologie, CHRU de Lille, 59000 Lille, France; Lille inflammation research international center (LIRIC), Inserm U995, université de Lille, 59000 Lille, France
| | - Bertrand Décaudin
- Institut de pharmacie, CHRU de Lille, rue Philippe-Marrache, 59000 Lille, France; EA 7365, groupe de recherche sur les formes injectables et les technologies associées (GRITA), université de Lille, 59000 Lille, France
| | - François Glowacki
- EA 4483, impact de l'environnement chimique sur la santé humaine (IMPECS), université de Lille, 59000 Lille, France; Service de néphrologie, CHRU de Lille, 59000 Lille, France
| | -
- Réseau Néphronor, CHRU de Lille, 59000 Lille, France
| |
Collapse
|